cephalosporin c has been researched along with ppi-0903 in 486 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (4.94) | 29.6817 |
| 2010's | 385 (79.22) | 24.3611 |
| 2020's | 77 (15.84) | 2.80 |
| Authors | Studies |
|---|---|
| Hashiguchi, S; Iizawa, Y; Ishikawa, T; Miyake, A; Nagai, J; Nakao, M; Okonogi, K | 1 |
| Fritsche, TR; Ge, Y; Jones, RN; Kaniga, K; Sader, HS | 2 |
| Ge, Y; Kaniga, K; Livermore, DM; Mushtaq, S; Warner, M | 1 |
| Bugnon, D; Caillon, J; Ge, JY; Hamel, A; Jacqueline, C; Le Mabecque, V; Miègeville, AF; Potel, G | 1 |
| Das, A; Ge, Y; Talbot, GH; Thye, D | 1 |
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Parish, D; Scheinfeld, N | 1 |
| Hesek, D; Lee, M; Mobashery, S; Vakulenko, SB; Villegas-Estrada, A | 1 |
| Biek, D; Ge, Y; Sahm, DF; Talbot, GH | 1 |
| Aguilar, L; Biek, D; Fenoll, A; Giménez, MJ; Granizo, JJ; Robledo, O; Tarragó, D | 1 |
| Ban, J; Hashiguchi, S; Horibe, H; Ikeda, Y; Ishikawa, T; Urayama, S | 1 |
| Beall, B; Biek, D; du Plessis, M; Ge, Y; Klugman, KP; Klugman, M; McGee, L; Smith, AM; Whitney, CG | 1 |
| Brown, SD; Traczewski, MM | 1 |
| Micek, ST; Neuner, EA; Ritchie, DJ | 1 |
| Ge, Y; Janes, R; Morrissey, I | 1 |
| Corey, GR; Kanafani, ZA | 1 |
| Jones, RN; Leonard, SN; Rybak, MJ; Sader, HS; Vidaillac, C | 1 |
| Gin, AS; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Rubinstein, E; Schweizer, F; Sniezek, G; Zelenitsky, S; Zhanel, GG | 1 |
| Green, K; Low, DE; McGeer, A; Patel, SN; Pillai, DR; Pong-Porter, S | 1 |
| Leonard, SN; Rybak, MJ; Vidaillac, C | 2 |
| Batard, E; Biek, D; Caillon, J; Ge, Y; Jacqueline, C; Le Mabecque, V; Miègeville, AF; Potel, G | 1 |
| Appelbaum, PC; Pankuch, GA | 1 |
| Ge, Y; Maynard, D; Rickert, DE | 1 |
| Kollef, MH | 1 |
| Livermore, DM; Mushtaq, S | 1 |
| Malouin, F; Moisan, H; Pruneau, M | 1 |
| Citron, DM; Goldstein, EJ; Merriam, CV; Tyrrell, KL | 3 |
| Appelbaum, PC; Kosowska-Shick, K; McGhee, PL | 1 |
| Asker-Hagelberg, C; Bäckström, T; Jandourek, A; Nord, CE; Panagiotidis, G; Weintraub, A | 1 |
| Bajaksouzian, S; Biek, D; Critchley, IA; Good, CE; Jacobs, MR; Jones, RN; Sader, HS; Windau, AR | 1 |
| Rybak, MJ; Steed, ME | 1 |
| Corey, GR; Nannini, EC; Stryjewski, ME | 1 |
| Johnson, L; Pawlak, J; Saravolatz, L | 1 |
| Critchley, I; Livermore, DM; Mushtaq, S; Warner, M; Williams, G | 1 |
| Amador, G; Batard, E; Biek, D; Caillon, J; Ge, Y; Hamel, A; Jacqueline, C; Le Mabecque, V; Miègeville, AF; Potel, G | 1 |
| Baculik, T; Corey, GR; Critchley, I; Das, AF; Friedland, HD; Talbot, GH; Thye, D; Wilcox, M; Witherell, GW | 1 |
| Amador, G; Batard, E; Biek, D; Caillon, J; Ge, Y; Jacqueline, C; Le Mabecque, V; Potel, G | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Critchley, I; Eckburg, PB; File, TM; Friedland, HD; Lee, J; Llorens, L; Low, DE; Talbot, GH; Thye, D | 1 |
| Bazan, JA; Martin, SI | 1 |
| Jones, RN; Mendes, RE; Sader, HS | 1 |
| Moellering, RC | 1 |
| Drusano, GL | 3 |
| Baculik, T; Corey, GR; Friedland, D; Talbot, GH; Thye, D; Wilcox, MH | 2 |
| Corrado, ML | 1 |
| Biek, D; Critchley, IA; Riccobene, TA; Thye, DA | 1 |
| Kanafani, ZA | 1 |
| Appelbaum, PC; Clark, C; Kosowska-Shick, K; McGhee, P | 1 |
| Chahine, EB | 1 |
| Brown, J; Lim, L; Sutton, E | 1 |
| Amador, G; Batard, E; Biek, D; Caillon, J; Jacqueline, C; Le Mabecque, V; Miègeville, AF; Potel, G | 1 |
| Adam, HJ; Decorby, MR; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Zhanel, GG | 1 |
| Jain, A; Kaushik, D; Rathi, S | 1 |
| Cox, L; Hoban, DJ; Karlowsky, JA; Nichol, K; Noreddin, AM; Rossnagel, E; Zelenitsky, S; Zhanel, GG | 1 |
| Johnson, LB; Saravolatz, LD; Stein, GE | 1 |
| Laudano, JB | 1 |
| Critchley, IA; Eckburg, PB; File, TM; Friedland, HD; Lee, J; Llorens, L; Low, DE; Talbot, GH; Thye, DA | 1 |
| Critchley, IA; David Friedland, H; Eckburg, PB; File, TM; Lee, J; Llorens, L; Low, DE; Talbot, GH; Thye, DA | 1 |
| Biek, D; Critchley, IA; Eckburg, PB; Friedland, HD; Jandourek, A; Thye, DA | 1 |
| Friedland, HD; Laudano, JB; Rank, DR | 1 |
| Farrell, DJ; Jones, RN; Mendes, RE; Sader, HS | 1 |
| Crandon, JL; Furtado, GH; Nicolau, DP; Williams, G; Wiskirchen, DE | 1 |
| Johnson, AP; Leibovici, L | 1 |
| Biek, D; Charles, PE; Chavanet, P; Croisier-Bertin, D; Ge, Y; Larribeau, A; Piroth, L | 1 |
| Rybak, MJ; Steed, M; Vidaillac, C | 1 |
| Lanfranco, OA; Levine, DP | 1 |
| Crandon, JL; Keel, RA; Nicolau, DP | 1 |
| Biek, D; Costello, AJ; Critchley, IA; Diekema, DJ; Doern, GV; Dohrn, CL; Heilmann, KP; Kroeger, JS; Riahi, F; Richter, SS | 1 |
| Chen, LF; DiMondi, VP; Drew, RH | 1 |
| Belavic, JM | 1 |
| Carver, PL; DePestel, DD; Jorgenson, MR | 1 |
| Brown, D; Castanheira, M; Critchley, I; Drusano, GL; Grasso, C; Jones, RN; Kulawy, R; Liu, W; Louie, A; Thye, D; Vanscoy, B; Williams, G | 1 |
| Chan, P; Dedhiya, MG; DiNunzio, J; Kupiec, TC; Laudano, JB; Singh, BN; Trissel, LA | 1 |
| Wilcox, MH | 1 |
| Hussar, DA | 1 |
| Cadena, J; Childs, LM; Gonzalez-Velez, M; Ho, TT; Lewis, JS | 1 |
| Biek, D; Eckburg, PB; Friedland, HD; Laudano, JB; Llorens, L; O'Neal, T; Rank, DR; Smith, A; Thye, D; Witherell, GW | 1 |
| Crandon, JL; Housman, ST; Keel, RA; Nicolau, DP; Williams, G | 1 |
| Biek, D; Rybak, MJ; Steed, ME; Vidaillac, C; Winterfield, P | 1 |
| Leakey, A; Morrissey, I | 1 |
| Nikitin, AV | 1 |
| Appelbaum, PC; Biek, D; Jones, RN; Kosowska-Shick, K; McGhee, P; Mendes, RE; Sader, HS; Tsakris, A | 1 |
| Barker, K; Hope, R; Livermore, DM; Mushtaq, S; Warner, M; Woodford, N | 1 |
| Chang, MH; Fung, HB; Poon, H | 1 |
| Adam, H; Hoban, DJ; Karlowsky, JA; Nichol, K; Noreddin, AM; Yachison, C; Zhanel, GG | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 9 |
| Diekema, DJ; Doern, GV; Dohrn, CL; Heilmann, KP; Riahi, F; Richter, SS | 2 |
| Casapao, AM; Levine, DP; Rybak, MJ; Steed, ME | 1 |
| Ahn, SH; Biek, D; Critchley, I; Fowler, VG; Lamlertthon, S; Llorens, L; Rude, T; Ruffin, F; Sharma-Kuinkel, BK; Tamarana, G; Tong, A; Tong, SY; Zhang, Y | 1 |
| Graviss, EA; Marconescu, P; Musher, DM | 1 |
| Castanheira, M; Farrell, DJ; Jones, RN; Mendes, RE; Sader, HS | 2 |
| Lodise, TP; Low, DE | 1 |
| Leakey, A; Morrissey, I; Northwood, JB | 1 |
| Aung, G; Fierer, J; Jahng, M; Johns, S; Lin, JC; Thomas, A | 1 |
| Andes, D; Berti, AD; Hutson, PR; Rose, WE; Schulz, LT; Shukla, SK; Striker, R | 1 |
| Corey, GR; Jones, RN | 1 |
| File, TM; Stein, GE; Wilcox, MH | 1 |
| Farrell, DJ; Jones, RN; Pfaller, MA; Sader, HS | 1 |
| Bhalodi, AA; Biek, D; Crandon, JL; Nicolau, DP | 1 |
| Flamm, RK; Jones, RN; Mendes, RE; Sader, HS | 2 |
| Flamm, RK; Jones, RN; Sader, HS; Stilwell, MG | 2 |
| Oberpichler-Schwenk, H | 1 |
| DeBellis, HF; Jones, MC; Kincaid, SE | 1 |
| Pogliano, J; Rose, WE; Rybak, MJ; Sakoulas, G; Tewhey, R; Werth, BJ | 1 |
| Giuliano, C; Johnson, LB; Kale-Pradhan, PB | 1 |
| Frère, JM; Zapun, A; Zervosen, A | 1 |
| Garrison, MW; Kawamura, NM; Wen, MM | 1 |
| Brown, M; Kong, F; Wang, H; Wang, Y; Xiao, M; Xu, YC; Yang, QW; Zhang, H; Zhao, HR; Zhao, Y | 1 |
| Das, D; Garcia, LG; Lemaire, S; Mélard, A; Rozenberg, R; Tulkens, PM; Van Bambeke, F | 1 |
| Rank, D; Riccobene, TA; Su, SF | 1 |
| Heidari, A; Jongsma, K; Joson, J | 1 |
| Eckburg, PB; Friedland, HD; Kollef, M; Llorens, L; Shorr, AF | 1 |
| Llorens, L; Rank, D; Rekeda, L; Riccobene, TA | 1 |
| Flamm, RK; Jones, RN; Sader, HS | 4 |
| Murray, KP; Newton, KL; Nonejuie, P; Pogliano, J; Rybak, MJ; Sakoulas, G; Vidaillac, C; Werth, BJ | 1 |
| Bowker, KE; MacGowan, AP; Noel, AR; Tomaselli, S | 2 |
| Kaatz, GW; Rybak, MJ; Steed, ME; Werth, BJ | 1 |
| Baines, SD; Chilton, CH; Crowther, GS; Freeman, J; Todhunter, SL; Wilcox, MH | 1 |
| Cook, PP; Frenkel, A; Rimawi, RH | 1 |
| Richards, EP; Sharff, KA; Townes, JM | 1 |
| Burdette, SD; Desai, KR; Hagaman, J; Pleiman, CM; Polenakovik, HM | 1 |
| Crum-Cianflone, N; Haddad, F; Nizet, V; Nonejuie, P; Pogliano, J; Sakoulas, G | 1 |
| Beresford, E; Friedland, HD; Huang, X; Lodise, T | 1 |
| Frampton, JE | 1 |
| Acosta, F; Cottagnoud, M; Cottagnoud, P; Stucki, A | 2 |
| Dalhoff, A; Schubert, S | 1 |
| Ambrose, PG; Bhavnani, SM; Forrest, A; Khariton, T; Reynolds, DK; Riccobene, T; Rubino, CM; Van Wart, SA | 1 |
| Adam, HJ; Baxter, MR; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Walkty, AJ; Zhanel, GG | 1 |
| Pleiman, CM; Polenakovik, HM | 1 |
| Bhalodi, AA; Crandon, JL; Nicolau, DP; Williams, G | 2 |
| Ambrose, PG; Bhavnani, SM; Forrest, A; Friedland, HD; Hammel, JP; Khariton, T; Reynolds, DK; Riccobene, TA; Rubino, CM; Van Wart, SA | 1 |
| Amoroso, A; Coyette, J; Frère, JM; Henry, X; Joris, B; Verlaine, O | 1 |
| Castanheira, M; Jones, RN; Sader, HS | 1 |
| David Friedland, H; Davis, A; Jandourek, A; Santos, PD; Smith, A | 1 |
| Carrasco-López, C; Chang, M; Dawley, M; Fisher, JF; Fishovitz, J; Hermoso, JA; Hesek, D; Johnson, JW; Kumarasiri, M; Lastochkin, E; Lee, M; Llarrull, LI; Mobashery, S; Otero, LH; Rojas-Altuve, A | 1 |
| Armstrong, J; Das, S; Edeki, T; Li, J; Mathews, D | 1 |
| Rybak, MJ; Werth, BJ | 1 |
| Bhalodi, AA; Hagihara, M; Kuti, JL; Nicolau, DP | 1 |
| Bucak, O; Ciftci, IH; Copur Çiçek, A; Durmaz, S; Güçkan, R; Güneş, H; Koçoğlu, E; Mengeloğlu, FZ; Taş, T; Terzi, HA; Yanık, K; Yavuz, MZ | 1 |
| Crispell, EK; Diekema, DJ; Doern, GV; Dohrn, CL; Heilmann, KP; McDanel, JS; Riahi, F; Richter, SS; Satola, SW | 1 |
| Ambrose, PG; Bhavnani, SM; Critchley, IA; Friedland, HD; Khariton, T; Riccobene, TA; Rubino, CM; Van Wart, SA | 1 |
| Christiansen, KJ; Coombs, GW; Pearson, JC; Robinson, JO | 1 |
| Livermore, DM; Mushtaq, S; Warner, M | 1 |
| Humphries, R; Nizet, V; Nonejuie, P; Olson, J; Pogliano, J; Rose, W; Sakoulas, G | 1 |
| Bucheit, J; Collins, R; Joshi, P | 1 |
| Badiou, C; Biek, D; Charles, PE; Chavanet, P; Croisier-Bertin, D; Da Silva, S; Dumitrescu, O; Guerard, P; Hayez, D; Labrousse, D; Lina, G; Piroth, L; Vandenesch, F | 1 |
| Jakate, A; Rank, D; Riccobene, T | 1 |
| Flamm, RK; Jones, RN; Pfaller, MA; Sader, HS | 1 |
| Dien Bard, J; Gold, HS; Hindler, JA; Limbago, B | 1 |
| Beresford, E; Biek, D; Friedland, HD; Jandourek, A; Mawal, Y; Riccobene, T | 1 |
| Engler, C; Maloney, S; Norton, R | 1 |
| Muscedere, J | 1 |
| Griffiths, CL; Gutierrez, KC; Lovell, RD; Pitt, RD | 1 |
| Barber, KE; Barr, VO; Casapao, AM; Davis, SL; Goff, DA; Kaye, KS; Klinker, KP; Molloy, LM; Mynatt, RP; Pogue, JM; Rybak, MJ | 1 |
| Eckburg, PB; Friedland, HD; Jandourek, A; Llorens, L; Smith, A; Thye, DA | 1 |
| Castanheira, M; Jones, RN; Sader, HS; Williams, G | 1 |
| Barber, KE; McRoberts, JP; Rybak, MJ; Werth, BJ | 1 |
| File, TM; Pasquale, TR; Tan, MJ; Trienski, TL | 1 |
| Johnson, LB; Martin, H; Pawlak, J; Saravolatz, LD; Saravolatz, SN | 1 |
| Cole, P; David Friedland, H; Evans, J; Jandourek, A; Ramani, A; Smith, A; Udeani, G | 1 |
| Barber, KE; Ireland, CE; Rybak, MJ; Werth, BJ | 1 |
| Alfandari, S; Boutoille, D; Dupont, M; Revest, M; Stahl, JP; Tattevin, P; Van Grunderbeeck, N; Vitrat, V | 1 |
| Cantón, R; Horcajada, JP | 1 |
| Cercenado, E; Morosini, MI | 1 |
| Grau, S; Luque, S; Sorlí, L | 1 |
| Canut, A; Martínez-Martínez, L | 1 |
| Barberán, J; Cisneros, JM | 1 |
| Cardenal, JA; Reinoso, JC | 1 |
| Calbo, E; Zaragoza, R | 1 |
| Almirante, B; Miró, JM; Pericás, JM | 1 |
| Chen, HH; Hon, PY; Hsu, LY | 1 |
| Alm, RA; Ambler, JE; Kahlmeter, G; Koeth, LM; Matuschek, E | 1 |
| Alm, RA; Iaconis, JP; Kos, VN; Lahiri, SD; McLaughlin, RE; Sader, HS | 1 |
| Chan, JD; Dellit, TH; Jain, R; Lynch, JB; Pottinger, PS; Rogers, L | 1 |
| Biek, D; Critchley, IA; Farrell, DJ; Jones, RN; Mendes, RE; Sader, HS | 1 |
| Brown, KR; Edmiston, CE; Graham, MB; Krepel, CJ; Leaper, D; Ledeboer, NA; Lee, C; Lewis, BD; Mackey, TL; Rossi, PJ; Seabrook, GR | 1 |
| Arshad, S; Hartman, P; Zervos, MJ | 1 |
| Carrasco-López, C; Chang, M; Dawley, M; Fishovitz, J; Hermoso, JA; Mobashery, S; Otero, LH; Rojas-Altuve, A | 1 |
| Bressler, AM; Casapao, AM; Dhand, A; Ebright, JR; Goff, DA; Johns, S; Kaatz, GW; Kullar, R; Lee, Y; Moise, PA; Nizet, V; Nonejuie, P; Okumura, CY; Olson, J; Pogliano, J; Rose, WE; Rybak, MJ; Sakoulas, G | 1 |
| Fernandez, R; Paz, LI; Rosato, AE; Rosato, RR | 1 |
| Broadhurst, H; Edeki, T; Kujacic, M; Li, J; Sunzel, M | 1 |
| Bonnin, P; Bru, JP; Desjoyaux, E; Janssen, C; Pagani, L; Vitrat, V | 1 |
| Ávila Alonso, A; Borrás Máñez, M; Bratos Pérez, MÁ; Colomina Rodríguez, J; de la Iglesia Salgado, A; de la Iglesia Salgado, M; Domínguez Castaño, A; Gil Tomás, J; Márquez Sanabria, A; Ortiz de Lejarazu Leonardo, R; Pérez Cáceres, JA; Saavedra Martín, JM; Tenorio-Abreu, A | 1 |
| Barber, KE; Rybak, MJ; Sakoulas, G | 1 |
| Crandon, JL; Nicolau, DP; So, W; Zhanel, GG | 1 |
| Crémieux, AC; Gatin, L; Ghout, I; Laurent, F; Saleh-Mghir, A; Tasse, J | 1 |
| Kwan, BK; Yam, FK | 1 |
| Cernoch, PL; Long, SW; Mehta, SC; Musick, WL; Musser, JM; Olsen, RJ; Palzkill, T; Perez, KK; Rosato, AE | 1 |
| Locati, J; Sangha, B; Sidhu, I; Sulaiman, K | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Sader, HS | 2 |
| Barber, KE; Rybak, MJ; Werth, BJ | 1 |
| Cole, P; Evans, J; Friedland, HD; Udeani, G | 1 |
| Sinipal'nikov, AI | 1 |
| Bajwa, RJ; Balouch, MA; Hassoun, A | 1 |
| Adelman, MH; Bader, J; Crane, JK; Jacobs, DM; Paladino, JA; Schentag, JJ; Shields, RK; Taylor, J; Wilton, GJ | 1 |
| Kuti, JL; MacVane, SH; Nicolau, DP; So, W | 1 |
| Stahlmann, R | 1 |
| Cole, P; Evans, JD; Friedland, HD; Udeani, G | 1 |
| Danziger, LH; Glowacki, RC; Merker, A; Rodvold, KA | 1 |
| Ambrose, PG; Bhavnani, SM; Drusano, GL; Forrest, A; Friedland, HD; Hammel, JP; Khariton, T; Reynolds, DK; Riccobene, TA; Rubino, CM; Van Wart, SA | 1 |
| Espedido, BA; Jensen, SO; van Hal, SJ | 1 |
| Calmaggi, A; Cannon, CM; Friedland, HD; Goldstein, EJ; Jandourek, A; Lipsky, BA; Ramani, A | 1 |
| Gallagher, JC; Kuriakose, SS; Rabbat, M | 1 |
| Greshake, D | 1 |
| Seifert, H | 1 |
| Eckmann, C | 2 |
| Welte, T | 1 |
| Albuszies, G; Klösel, S | 1 |
| Cole, P; Friedland, HD; Maggiore, C; Pasquale, T | 1 |
| Anzueto, AR; File, TM; Huang, X; Lodise, TP; Shorr, AF; Smith, A; Weber, DJ; Yang, M; Zhao, Q | 1 |
| Ávila, A; Colomina, J; Gil, J; Ortiz de Lejarazu, R; Tenorio-Abreu, A | 1 |
| Chiang, CH; D'Souza, G; Iaconis, J; Lan, NH; Lee, SH; Melnick, D; Sun, F; Sun, T; Wilson, D; Zhong, NS; Zhuo, C | 1 |
| Corey, GR; Jones, RN; Stryjewski, ME | 1 |
| Barras, C; Jousselin, A; Kelley, WL; Lelong, E; Renzoni, A | 1 |
| Alonto, A; Jones, JM; Leedahl, DD; Richter, LM | 1 |
| Kullar, R; Nizet, V; Nonejuie, P; Pogliano, J; Rybak, MJ; Sakoulas, G | 1 |
| Critchley, IA; Holliday, NM; Jones, RN | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS; Streit, JM | 1 |
| Kong, F; Mao, LL; O'Sullivan, MV; Wang, H; Xiao, M; Xu, YC; Zhang, H; Zhao, HR; Zhao, Y | 1 |
| Arena, F; Giani, T; Landini, G; Pallecchi, L; Riccobono, E; Rossolini, GM | 1 |
| Canut, A; Isla, A; Rodríguez-Gascón, A | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Sader, HS | 1 |
| Arthur, M; Cortes, M; Dubée, V; Gutmann, L; Hugonnet, JE; Lefebvre, AL; Mainardi, JL; Soroka, D | 1 |
| Abdelhamed, AM; Bajaksouzian, S; Bonomo, RA; Foster, AN; Gatta, JA; Jacobs, MR; Nichols, WW; Papp-Wallace, KM; Testa, R; Winkler, ML | 1 |
| Basuino, L; Chambers, HF; Chan, LC; Chatterjee, SS; Diep, B; Hamilton, S | 1 |
| Barber, KE; Raut, A; Rybak, MJ; Smith, JR | 1 |
| Baxi, SM; Chan, D; Jain, V | 1 |
| Cole, P; Friedland, HD; Guervil, DJ; Hassoun, A; Huang, XY; Kaye, KS | 1 |
| Bill, C; Havlichek, D; Scharmen, A; Smith, C; Stein, GE; Yasin, F | 1 |
| Mahfood Haddad, T; Sundaragiri, PR; Vallabhajosyula, S; Vivekanandan, R | 1 |
| Gomes, DM; LaPlante, KL; Ward, KE | 1 |
| Danziger, LH; Justo, JA; Mayer, SM; Novak, RM; Pai, MP; Rodvold, KA; Soriano, MM | 1 |
| Ansari, M; Gilani, M; Hafeez, A; Latif, M; Munir, T; Najeeb, S; Rehman, S; Saad, N | 1 |
| Ensom, MH; Kiang, TK; Wilby, KJ | 1 |
| Abbott, AN; Werth, BJ | 1 |
| Klare, I; Layer, F; Strommenger, B; Werner, G | 1 |
| Cole, P; Friedland, HD; Kaye, KS; Udeani, G | 1 |
| Andresen, D; Harkness, J; Iredell, JR; Isaia, L; Marriott, D; Mubarak, N; O'Sullivan, M; Sandaradura, I; Zhou, F | 1 |
| Barber, KE; Boles, BR; Ireland, CE; Rose, WE; Rybak, MJ; Smith, JR | 1 |
| Cates, JE; Li, G; Mitrani-Gold, FS; Mundy, LM | 1 |
| Nord, CE; Panagiotidis, G; Rashid, MU; Rosenborg, S; Söderberg-Löfdal, K; Weintraub, A | 1 |
| Shandurenko, IN | 1 |
| Chua, J; Lei, LR; Sakoulas, G; Varada, NL | 1 |
| Alm, RA; Ambler, JE; Lahiri, SD; McLaughlin, RE; Whiteaker, JD | 1 |
| Cunha, BA; Gran, A | 1 |
| Alm, RA; Lahiri, SD | 3 |
| James, D; Kearns, A; Livermore, DM; Mushtaq, S; Warner, M; Woodford, N | 1 |
| Edeki, T; Li, H; Li, J; Sunzel, M; Wilson, D; Xu, P; Yang, L | 1 |
| Ghamrawi, RJ; Neuner, E; Rehm, SJ | 1 |
| Baos, E; Candel, FJ; Nieto, M; Picazo, JJ | 1 |
| Amicosante, G; Marcoccia, F; Segatore, B; Setacci, D | 1 |
| James, D; Livermore, DM; Mushtaq, S; Warner, M; Woodford, N | 1 |
| Abbott, IJ; Holt, DC; Jenney, AW; Jeremiah, CJ; Kandiah, JP; Mirčeta, M; Spelman, DW; Tong, SY | 1 |
| Alm, RA; Ambler, JE; Biedenbach, DJ; Bouchillon, SK; Hoban, DJ; Lahiri, SD; Reiszner, E; Sahm, DF | 2 |
| Alabi, A; Becker, K; Idelevich, EA; Peters, G; Schaumburg, F | 1 |
| Ba, X; Blane, B; Ellington, MJ; Harrison, EM; Hill, RL; Holmes, MA; Loeffler, A; Peacock, SJ | 1 |
| Anderson, SW; LaVie, KW; O'Neal, CS; O'Neal, HR; Rice, TW; Saavedra, TC | 1 |
| Biedenbach, DJ; Bouchillon, SK; Iaconis, JP; Karlowsky, JA; Reiszner, E; Sahm, DF | 1 |
| Bouquié, R; Boutoille, D; Caillon, J; Dailly, E; Deslandes, G; Grégoire, M; Jolliet, P; Leroy, AG; Malandain, D; Renaud, C | 1 |
| Bilgin, K; Birinci, A; Eroglu, C; Guluzade, E; Gunaydin, M; Karadag, A; Yanik, K | 1 |
| Esterbrooks, DJ; Haddad, TM; Sundaragiri, PR; Vallabhajosyula, S | 1 |
| Edeki, T; Learoyd, M; Li, J; Li, Y; Ngo, N; Sunzel, M | 1 |
| Greenwood-Quaintance, KE; Park, KH; Patel, R | 1 |
| Chung, SJ; Kwa, AL; Lim, TP | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Rhomberg, PR; Sader, HS | 1 |
| File, TM; Friedland, HD; Iaconis, JP; Llorens, L; Melnick, D; Sun, F; Taboada, M; Wilson, D; Zhong, NS | 1 |
| Farhat, NM; Hutchinson, LS; Peters, M | 1 |
| Anstead, MI; Autry, EB; Burgess, DR; Gardner, BM; Kuhn, RJ; Leung, NR; Rybak, JM | 1 |
| Acosta, F; Icardo, JM; Lázaro-Díez, M; Martínez-Martínez, L; Ramos-Vivas, J; Remuzgo-Martínez, S; Rodríguez-Mirones, C | 1 |
| Bugajski, P; Greberski, K; Jarząbek, R; Kalawski, R; Kilanowska, M; Rzymski, S | 1 |
| Atwood, DN; Beenken, KE; Lantz, TL; Lynn, WB; Meeker, DG; Mills, WB; Smeltzer, MS; Spencer, HJ | 1 |
| Anandan, S; Bakthavatchalam, YD; Chaudhuri, BN; Chitnis, DS; Joshi, S; Pragasam, AK; Roy, I; Tapan, D; Veeraraghavan, B | 1 |
| Becker, K; Idelevich, EA; Knaack, D; Mutter, W; Peschel, A; Peters, G; Schaumburg, F; Scherzinger, AS | 1 |
| Raut, A; Rybak, MJ; Smith, JR; Yim, J | 1 |
| Allison, GM; Mendes, RE; Sader, HS; Sanchez, EH | 1 |
| Chambers, HF; Chan, LC; Chatterjee, SS; Chiu, CY; Greninger, AL; Hamilton, SM | 1 |
| LaPlante, KL; Luther, MK; Rice, LB | 1 |
| Battersby, A; Gibson, E; Hackett, J; Karve, S; Levinson, J | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Sader, HS; Streit, JM | 1 |
| Lackner, E; Lagler, H; Matzneller, P; Österreicher, Z; Wulkersdorfer, B; Zeitlinger, M | 1 |
| Ashbaugh, CD; Barra, M; Furtek, KJ; Koo, S; Kubiak, DW; Varughese, CA | 1 |
| Blumer, JL; Bradley, JS; Cannavino, C; Friedland, HD; Ghonghadze, T; Jandourek, A; O'Neal, T | 1 |
| Concia, E; Falcone, M; Giusti, M; Mazzone, A; Santini, C; Stefani, S; Violi, F | 1 |
| Bradley, JS; Cannavino, CR; Friedland, HD; Jandourek, A; Kaplan, SL; Korczowski, B; Nemeth, A; O'Neal, T | 1 |
| Antadze, T; Bradley, JS; Giorgobiani, M; Jandourek, A; Korczowski, B; O'Neal, T; Smith, A; Stryjewski, ME | 1 |
| Deresinski, S; Holubar, M; Meng, L | 1 |
| Krause, KM; Nichols, WW; Pillar, CM; Shinabarger, DL; Stoneburner, A | 1 |
| Alm, RA; Ambler, J; Apfalter, P; Becker, K; Gesu, G; Iaconis, J; Koeth, LM; Lahiri, SD; Martínez-Martínez, L | 1 |
| Hahn, AW; Jain, R; Spach, DH | 1 |
| Cavaco-Silva, P; Matias, CS; Melo-Cristino, J; Mendes, JJ; Mottola, C; Oliveira, M; Tavares, L | 1 |
| Cannatelli, A; Di Pilato, V; Giani, T; Nichols, WW; Rossolini, GM; Testa, R | 1 |
| Di Vincenzo, S; Ferraro, M; Gjomarkaj, M; Pace, E; Siena, L | 1 |
| Jandourek, A; Khariton, T; Knebel, W; Pushkin, R; Riccobene, TA | 1 |
| Armengol-Porta, M; Bandt, D; Coleman, DC; Ehricht, R; Gavier-Widen, D; Hotzel, H; Kinnevey, P; Lazaris, A; Monecke, S; Peters, M; Rangstrup-Christensen, L; Schlotter, K; Shore, AC; Tenorio-Abreu, A | 1 |
| Fang, H; Fröding, I; Gian, B; Hæggman, S; Nord, CE; Tollström, UB; Ullberg, M | 1 |
| Biedenbach, DJ; Bouchillon, SK; Hackel, M; Iaconis, JP; Karlowsky, JA; Sahm, DF | 1 |
| Bradley, JS; Carrothers, TJ; Das, S; Jandourek, A; Khariton, T; Knebel, W; Li, J; Riccobene, TA | 1 |
| Burnett, YJ; Echevarria, K; Traugott, KA | 1 |
| Bordi, E; D'Arezzo, S; De Giuli, C; Di Caro, A; Mazzarelli, A; Nisii, C; Paglia, MG; Petrosillo, N; Taglietti, F; Venditti, C; Vulcano, A | 1 |
| Athans, V; Davis, SL; Kenney, RM; Wong, J | 1 |
| Candel, FJ; Chiarella, F; García, AB; López, L; Viñuela-Prieto, JM | 1 |
| Dryden, M; Gonzalez, J; Iaconis, JP; Wilson, D; Zhang, Y | 1 |
| Argudín, MA; de Mendonça, R; Denis, O; Deplano, A; Dodémont, M; Nonhoff, C; Roisin, S; Taguemount, M | 1 |
| Andrey, DO; Bonetti, EJ; François, P; Harbarth, S; Kelley, WL; Manzano, C; Renzoni, A; Schrenzel, J | 1 |
| Scott, LJ | 1 |
| Ghazi, I; Hamada, Y; Nicolau, DP | 1 |
| Cantón, R; Díaz-Regañón, J; Livermore, DM; Morosini, MI; Rossolini, GM | 1 |
| Casapao, AM; Claeys, KC; Davis, SL; Klinker, KP; Lagnf, AM; Rybak, MJ; Sabagha, N; Trinh, TD; Zasowski, EJ | 1 |
| Altshuler, J; Fedorenko, M; Gritsenko, D; Ruhe, JJ | 1 |
| Bowker, K; MacGowan, A; Noel, A; Tomaselli, S | 1 |
| El Hajj, MS; Turgeon, RD; Wilby, KJ | 1 |
| Arber, M; Barata, T; Eales, J; Fleetwood, K; Glanville, J; Gould, IM; Kauf, TL; McCool, R | 1 |
| Arthur, M; Ourghanlian, C; Soroka, D | 1 |
| Domínguez-Herrera, J; Labrador-Herrera, G; López-Rojas, R; Pachón, J; Smani, Y | 1 |
| Arshad, S; Hartman, P; Huang, V; Moreno, D; Perri, MB; Zervos, MJ | 1 |
| Barber, KE; Stover, KR; White, BP | 1 |
| Arias, CA; Carvajal, LP; Chambers, HF; Diaz, L; Garavito, JD; Miller, WR; Munita, JM; Nigo, M; Panesso, D; Rios, R; Tran, TT; Wanger, A; Weinstock, G | 1 |
| Balada-Llasat, JM; Bauer, KA; Bremmer, DN; Goff, DA | 1 |
| Rademacher, J; Welte, T | 1 |
| Alam, M; Cady, B; De Silva, A; Mada, PK | 1 |
| Corey, A; So, TY | 1 |
| Castanheira, M; Flamm, RK; Jones, RN; Mendes, RE; Pfaller, MA; Sader, HS | 1 |
| Ashbaugh, AG; Jain, SK; Miller, LS; Miller, RJ; Ordonez, AA; Ortines, RV; Saini, V; Sterling, RS; Thompson, JM; Wang, Y | 1 |
| Eckburg, PB; File, TM; Friedland, HD; Llorens, L; Talbot, GH | 1 |
| Flamm, RK; Mendes, RE; Sader, HS; Streit, JM | 1 |
| Bollinger, M; Britt, RS; Evoy, KE; Frei, CR; Jones, X; Lee, GC; Reveles, KR; Sorensen, KM | 1 |
| Asseray, N; Bémer, P; Boutoille, D; Corvec, S; Dinh, A; Ferry, T; Laurent, F; Lustig, S; Malandain, D; Touchais, S | 1 |
| Chang, E; Lalikian, K; Parsiani, R; Turner, RB; Won, R | 1 |
| Azharuddin, M; Mathur, A; Prudence, D; Shukla, PS | 1 |
| Bruno, A; Cipollina, C; Di Gaudio, F; Di Vincenzo, S; Dino, P; Gjomarkaj, M; Pace, E; Siena, L | 1 |
| Bus, K; Karpiuk, I; Kiljan, M; Michalska, K; Tyski, S | 1 |
| Ahmad, Z; Distler, E; Patel, M; Swofford, B | 1 |
| Chapagain, ML; Cirrincione, KN; Deshpande, D; Gumbo, T; Lee, PS; Pasipanodya, JG; Srivastava, S | 1 |
| Abad, L; Benito, Y; Bes, M; Camus, C; Chidiac, C; Dupieux, C; Ferry, T; Laurent, F; Lustig, S; Trouillet-Assant, S; Valour, F | 1 |
| Jansen, JW; Moenster, RP | 1 |
| Bloom, A; DeYoung, H; Tamayo, S | 1 |
| Bernhardt, J; Gonzalez, D; Jhaveri, R; Laughon, M; Massaro, M; Salerno, SN | 1 |
| Alm, RA; Almutairi, M; Ambler, JE; Chen, A; Lahiri, SD; San Martin, M; Singh, R | 1 |
| Barsky, EE; Goobie, SM; McAdam, AJ; Pereira, LM; Priebe, GP; Sawicki, GS; Sullivan, KJ; Wong, A | 1 |
| Duncan, LR; Flamm, RK; Mendes, RE; Pfaller, MA; Sader, HS | 1 |
| Gostev, V; Kalinogorskaya, O; Kruglov, A; Lobzin, Y; Sidorenko, S | 1 |
| Chan, D; Chang, E; Saedi-Kwon, H; Schwartz, J; Turner, RB; Wilson, DE; Won, R | 1 |
| Bonomo, RA; Burdette, SD; Haller, NA; Horattas, S; Mangira, C; Salata, RA; Watkins, RR; Yendewa, G | 1 |
| Chopra, A; Cies, JJ; Enache, A; Moore, WS | 1 |
| Hartung, A; Klinger-Strobel, M; Makarewicz, O; Pletz, MW; Stein, C; Thieme, L | 1 |
| Cortes-Penfield, N; Hunter, A; Oliver, NT; Rodriguez-Barradas, M | 1 |
| Rybak, MJ; Tran, N | 1 |
| Alvarez, DN; Bayer, AS; Farah, S; Garcia-de-la-Maria, C; Miro, JM; Mishra, NN; Sakoulas, G; Zapata, B | 1 |
| Chopra, A; Cies, JJ; Enache, A; Giliam, N; Low, T; Moore, WS | 1 |
| Drewry, DH; Ferrer, CA; Rose, WE; Sauer, JD; Schaenzer, AJ; Striker, R; Wlodarchak, N; Zuercher, WJ | 1 |
| Doyle, TB; Flamm, RK; Mendes, RE; Rhomberg, PR; Sader, HS | 1 |
| Arca-Suárez, J; Galán-Sánchez, F; González-Gómez, MC; Rodríguez-Iglesias, M; Soler-Gómez, A | 1 |
| Aliberti, S; Blasi, F; Di Pasquale, M; Gramegna, A; Mantero, M; Saderi, L; Sotgiu, G; Trogu, F | 1 |
| Das, S; Iaconis, J; Li, J; Melnick, D; Stone, GG; Yan, JL; Zhou, D | 1 |
| Cheng, J; Feng, X; Hu, Y; Huang, W; Huang, X; Jin, Y; Liao, K; Liu, Y; Lu, J; Xu, Y; Yang, Q; Yu, Y; Zhang, S; Zhou, M | 1 |
| Andreoni, F; Eberl, L; François, P; Kalawong, R; Mairpady Shambat, S; Menzi, C; Toyofuku, M; Zinkernagel, AS | 1 |
| Bouhemad, B; Chauzy, A; Chavanet, P; Combes, JC; Couet, W; Defrance, N; Nadji, A | 1 |
| Cheng, K; Hammond, J; Pypstra, R; Yan, JL | 1 |
| Destache, CJ; Guervil, DJ; Kaye, KS | 1 |
| Corey, GR; Das, S; Dryden, M; Friedland, HD; Gonzalez, J; Iaconis, J; Jandourek, A; Wilcox, MH; Wilson, DJ | 1 |
| Cuénod, A; Egli, A; Hinic, V; Khanna, N; Kuehl, R; Morgenstern, M; Wüthrich, D | 1 |
| Guervil, DJ; Johnson, LB; Ramani, A | 1 |
| Jamal, M; Nesher, L; Prince, RA; Raad, I; Rice, SA; Rolston, KVI; Rybak, MJ | 1 |
| Bhowmick, T; Boruchoff, SE; Imp, B; Liu, C; Sharma, R | 1 |
| Stone, GG; Urbán, E | 1 |
| Lede, R; Rosanova, MT; Sberna, N | 1 |
| Gil Romero, Y; Gómez-Garcés, JL | 1 |
| Alharbi, A; Asfour, HZ; Basilim, A; Eljaaly, K; Wali, H | 1 |
| Agnelli, F; Baratta, F; Colombo, F; Frantellizzi, V; Pani, A; Pastori, D; Scaglione, F | 1 |
| Bongiorno, D; Campanile, F; Mongelli, G; Stefani, S | 1 |
| Croxatto, A; Duss, FR; Garcia de la Mària, C; Giulieri, S; Lamoth, F; Manuel, O; Miró, JM | 1 |
| Barberán, J; Llinares, P; Mensa, J | 1 |
| Hammond, J; Kantecki, M; Stone, GG; Welte, T | 1 |
| Claeys, KC; Davis, SL; Delaportes, DJ; Estrada, SJ; Huang, V; Jorgensen, SCJ; Kaye, KS; Klinker, KP; Lagnf, AM; Rybak, MJ; Trinh, TD; Zasowski, EJ | 1 |
| Bae, IG; Stone, GG | 1 |
| Chow, S; Johns, ST; Martin, TCS; Mehta, SR | 1 |
| Awad, AR; Elawady, BA; ElFeky, DS; Elshobaky, MA | 1 |
| Karahan, ZC; Ozmen Capin, BB; Tekeli, A | 1 |
| Epps, KL; Epps, QJ; Young, DC; Zobell, JT | 1 |
| Chambers, HF; Deresinski, S; Holubar, M; Kalil, AC | 1 |
| Geriak, M; Haddad, F; Kullar, R; LaPlante, K; Nizet, V; Rose, W; Sakoulas, G; Zervos, M | 1 |
| Drusano, G; Kaye, KS; Patel, T | 1 |
| Jones, RN; Sader, HS | 1 |
| Gomart, C; Hulin, A; Martin, M; Mounier, R; Roujansky, A | 1 |
| Cuba, GT; da Costa, TM; Dos Santos, KRN; Kiffer, CRV; Morgado, PGM; Nicolau, DP; Nouér, SA | 1 |
| Chao, CM; Lai, CC; Lin, WT | 1 |
| Iredell, JR; Khalid, A; Lin, RCY; Lubián, AF; Ma, L | 1 |
| Amaro, R; Bassetti, M; Cilloniz, C; Giacobbe, DR; Graziano, E; Russo, A; Soriano, A; Torres, A; Vena, A | 1 |
| Arda, B; Aydemir, S; Bolat, E; Mermer, S; Pullukcu, H; Sipahi, H; Sipahi, OR; Turhan, T; Ulusoy, S; Yamazhan, T | 1 |
| Bradley, JS; Chan, PLS; Hammond, J; Hendrick, VM; Leister-Tebbe, HK; Mas Casullo, V; Raber, SR; Riccobene, T; Stone, GG; Yan, JL | 1 |
| Copa-Patiño, JL; Cuadros-González, J; Pérez-Serrano, J; Romanyk, J; Soliveri, J; TesfaMariam, A; Verdú-Expósito, C | 1 |
| Hartung, A; Makarewicz, O; Pletz, MW; Thieme, L | 1 |
| Alzueta, N; Castresana, M; Echeverria, A; Gascón, A; Marin, M; Pío, M | 1 |
| Hsueh, PR; Jean, SS; Ko, WC | 1 |
| Hsueh, PR; Jean, SS; Ko, WC; Lee, WS | 1 |
| Arias, CA; Dinh, AQ; Kebriaei, R; Khan, A; Murray, BE; Rice, SA; Rybak, MJ; Singh, KV; Stamper, KC; Tran, TT | 1 |
| Alosaimy, S; Lagnf, AM; Morrisette, T; Rybak, MJ | 1 |
| Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS; Streit, JM | 1 |
| Carniel, E; Oliveira, DS; Perez, LRR | 1 |
| Horner, C; Livermore, DM; Mushtaq, S | 1 |
| Anguita-Santos, F; Aznarte-Padial, MP; Borreguero, I; Castón, JJ; Corzo-Delgado, JE; Esteban-Moreno, MÁ; Herrero-Rodríguez, C; Jiménez-Aguilar, P; López-Cárdenas, S; Maldonado, N; Martín-Aspas, A; Martínez-Marcos, FJ; Ojeda-Burgos, G; Palacios-Baena, ZR; Praena-Segovia, J; Retamar, P; Rodríguez-Baño, J; Rosso-Fernández, CM; Valiente de Santis, L | 1 |
| Benner, K; Branstetter, J; Crowder, C; Searcy, H; Troxler, B; Yarbrough, A | 1 |
| Alfouzan, W; Boswihi, SS; Dhar, R; Udo, E | 1 |
| Herc, ES; Hutton, MA; Perri, MB; Sundaram, A; Zervos, MJ | 1 |
| Fernández, J; García-Carús, E; Rodríguez-Esteban, MÁ; Rodríguez-García, R; Telenti, M | 1 |
| Alegria, W; Deresinski, S; Holubar, M; Meng, L | 1 |
| Bassetti, M; Giacobbe, DR; Pelosi, P; Robba, C; Vena, A | 1 |
| Davis, JJ; Hernandez, RE; Hoffman, LR; Long, SW; Roch, M; Rosato, AE; Rosato, RR; Rose, WE; Saavedra, MO; Taglialegna, A; Varela, MC | 1 |
| Cheng, J; Duan, S; Jia, P; Jing, R; Kang, W; Liu, Y; Wang, T; Xu, Y; Yang, Q; Zhang, G; Zhang, H; Zhang, J; Zhu, Y | 1 |
| Algorri, M; Wong-Beringer, A | 1 |
| Cowart, MC; Ferguson, CL; Jordan-Villegas, A; Laham, F | 1 |
| Darban-Sarokhalil, D; Ghaznavi-Rad, E; Khoshbayan, A; Shariati, A; van Belkum, A | 1 |
| Kumar, R; Kumar, V; Lee, KW | 1 |
| Bouchillon, SLK; Hackel, MA; Karlowsky, JA; Kotb, REM; Lowman, W; Mohamed, N; Sahm, DF; Stone, GG | 1 |
| Ali, F; Gopalakrishnan, M; Guo, D; Heavner, M; Jean, W; Kalaria, S; Li, M; Medlin, C; Shu, Y; Williford, S; Yeung, SYA | 1 |
| Carrothers, TJ; Chan, PLS; Knebel, W; Raber, S; Riccobene, TA | 1 |
| Alonso Álvarez, A; Castelo Corral, LM; Míguez Rey, E; Padín Trigo, A; Ramos Merino, L; Sánchez Vidal, E; Sousa Regueiro, D | 1 |
| Huang, M; Johnson, TM; Kiser, TH; Miller, MA; Molina, KC; Mueller, SW | 1 |
| Dahdouh, E; Díaz-Pollán, B; Falces-Romero, I; Gómez-Gil, R; Mingorance, J | 1 |
| Piérard, D; Stone, GG | 1 |
| Kagkalou, G; Mantzana, P; Meletis, G; Protonotariou, E; Skoura, L; Tsoha, A; Tychala, A; Vasilaki, O | 1 |
| Al Jalali, V; Andreas, M; Böhmdorfer, M; Edlinger-Stanger, M; Hutschala, D; Jäger, W; Zeitlinger, M | 1 |
| Hsueh, PR; Huang, YT; Kuo, YW; Liao, CH; Teng, LJ | 1 |
| Guo, G; Huang, P; Ke, M; Lin, C; Wu, W; Xu, J; Ye, L; You, X; Zhou, J | 1 |
| De Puysseleyr, L; Ebo, DG; Elst, J; Faber, MA; Hagendorens, MM; Mertens, CM; Romano, A; Sabato, V; van der Poorten, MM | 1 |
| Carrothers, TJ; Esposito, S; Kantecki, M; Riccobene, T; Stone, GG | 1 |
| Soriano, A | 1 |
| Andrea, T; Bremmer, DN; Cain, AR; Finoli, LM; Guarascio, A; Ogbebor, O; Shively, NR | 1 |
| Cilloniz, C; Gabarrus, A; Garcia-Vidal, C; Mendez, R; Menéndez, R; Peroni, H; Rico, V; Soriano, A; Torres, A | 1 |
| Hung, WC; Lin, SY; Lo, SH; Lu, PL; Tseng, YT | 1 |
| Dryden, M; Kantecki, M; Leister-Tebbe, H; Stone, GG; Wilcox, M; Yan, JL | 1 |
| Esquivel, MD; Finklea, JD; Monogue, ML; Sanders, JM; Smith, GS | 1 |
| Abate, G; Frisby, J; Wang, G | 1 |
| Brandariz-Núñez, D; Fernández-Oliveira, C; Gutiérrez-Urbón, JM; Margusino, L; Martín-Herranz, I; Suanzes, J | 1 |
| Barceló-Vidal, J; Bonaga, B; Grau, S; Sánchez Montori, L | 1 |
| Cilloniz, C; Pericàs, JM; Rojas, J | 1 |
| Chang, SC; Chen, YC; Chuang, YC; Sheng, WH; Tsai, CE; Wang, JT; Yang, CJ | 1 |
| Artés, JF; de Pedro, MB; Galleymore, PR; Martín-Cerezuela, M; Padrós Olmedo, MŸ; Piqueres, SP | 1 |
| Aubry, A; Bémer, P; Boutoille, D; Corvec, S; Deschanvres, C; Guillouzouic, A; Lakhal, K; Lecomte, R; Lepoivre, T; Navas, D; Ruffier d'Epenoux, L; Tessier, E | 1 |
| Ashenoune, K; Boisson, M; Chauzy, A; Couet, W; Dahyot-Fizelier, C; Ferrandière, M; Gregoire, N; Lasocki, S; Marchand, S; Mimoz, O; Seguin, P | 1 |
| Cusumano, JA; Daffinee, KE; Desbonnet, C; García-Solache, M; LaPlante, KL; Piehl, EC; Rice, LB | 1 |
| Flores, AR; Hulten, KG; Kaplan, SL; McNeil, JC; Sommer, LM; Vallejo, JG | 1 |
| Cheng, B; Guo, P; Jia, P; Xu, Y; Yang, Q; Zhang, H; Zhu, Y | 1 |
| Mykietuk, A; Nannini, EC; Obed, MN; Toresani, I | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
| Blaine, BE; Kufel, WD; Mahapatra, R; Paolino, KM; Parsels, KA; Steele, JM; Thomas, SJ | 1 |
| Bradley, J; Huynh, HK; Maher, JM; Mendes, RE; Porsch, EA; St Geme Iii, JW; Yagupsky, P | 1 |
| Giamarellos-Bourboulis, EJ; Leventogiannis, K; Mouktaroudi, M | 1 |
| Sachu, A | 1 |
| Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB | 1 |
| Alonso Álvarez, A; Llinares Modéjar, P; Míguez Rey, E; Ramos Merino, L; Sánchez Vidal, E; Serrano Areba, J; Sousa Regueiro, D | 1 |
| Andini, R; De Gregorio, F; Durante-Mangoni, E; Esitini, D; Gallo, R; Iossa, D; Karruli, A; Marrazzo, T; Moretto, SM; Salemme, A; Zampino, R | 1 |
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
| Benítez-Cano, A; De-Antonio, M; Fresán, D; Grau, S; Horcajada, JP; Luque, S; Montero, MM; Roberts, JA; Sorlí, L; Vega, V | 1 |
65 review(s) available for cephalosporin c and ppi-0903
| Article | Year |
|---|---|
New antibiotics for healthcare-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
Ceftaroline: a cephalosporin with expanded Gram-positive activity.
Topics: Adult; Animals; Ceftaroline; Cephalosporins; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Mice; Skin Diseases, Bacterial; Treatment Outcome | 2009 |
Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections | 2009 |
New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.
Topics: Ceftaroline; Cephalosporins; Gram-Positive Bacteria; Humans; Methicillin Resistance; Staphylococcal Infections; Staphylococcus aureus | 2010 |
Ceftaroline fosamil: a novel broad-spectrum cephalosporin.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests | 2010 |
Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome | 2010 |
Ceftaroline: a new broad-spectrum cephalosporin.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests | 2011 |
Ceftaroline: a comprehensive update.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Drug Approval; Humans; Pneumonia, Bacterial; Prodrugs; Skin Diseases, Bacterial; Soft Tissue Infections; United States | 2011 |
Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Topics: Adult; Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Rabbits; Staphylococcal Infections; Streptococcus pneumoniae | 2011 |
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Pneumonia, Bacterial; Prodrugs; Skin Diseases, Bacterial; Soft Tissue Infections; United States | 2011 |
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Treatment Outcome | 2011 |
What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia?
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Community-Acquired Infections; Hospitalization; Humans; Pneumonia, Bacterial | 2011 |
Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Topics: Animals; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Drug Evaluation, Preclinical; Humans; Methicillin-Resistant Staphylococcus aureus; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Staphylococcal Infections | 2011 |
MRSA new treatments on the horizon: current status.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Teicoplanin | 2011 |
[Ceftaroline fosamil, a broad spectrum cephalosporin antibiotic for the treatment of community-acquired pneumonia and complicated skin and skin structure infections].
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Skin Diseases, Bacterial | 2011 |
Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Area Under Curve; Ceftaroline; Cephalosporins; Half-Life; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2012 |
Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Pneumonia, Bacterial; Skin Diseases, Bacterial | 2012 |
Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Double-Blind Method; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial | 2012 |
Summary of ceftaroline fosamil clinical trial studies and clinical safety.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Humans; Pneumonia, Bacterial; Staphylococcal Skin Infections | 2012 |
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus pneumoniae | 2012 |
Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rabbits; Staphylococcal Infections | 2012 |
Clinical management of septic arthritis.
Topics: Acetamides; Anti-Bacterial Agents; Arthritis, Infectious; Bacterial Infections; Ceftaroline; Cephalosporins; Daptomycin; Drug Therapy, Combination; Humans; Immunologic Factors; Linezolid; Methicillin-Resistant Staphylococcus aureus; Oxazolidinones; Risk Factors; Staphylococcal Infections; Treatment Outcome; Virginiamycin | 2013 |
Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Humans; Pneumonia; Skin Diseases, Infectious; Soft Tissue Infections | 2013 |
Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Staphylococcal Infections; Treatment Outcome; Young Adult | 2013 |
Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
Topics: Acute Disease; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Approval; Drug Design; Drug Interactions; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Staphylococcal Infections; United States; United States Food and Drug Administration | 2014 |
[Pharmacokinetics and pharmacodynamics of ceftaroline].
Topics: Ceftaroline; Cephalosporins; Humans | 2014 |
[Role of ceftaroline fosamil in the treatment of bacteremia and infectious endocarditis].
Topics: Animals; Bacteremia; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Disease Models, Animal; Endocarditis, Bacterial; Humans; Staphylococcal Infections | 2014 |
Ceftaroline--An Anti-MRSA Cephalosporin and Its Implications for Singapore.
Topics: Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Singapore; Staphylococcal Infections | 2014 |
High incidence of discontinuations due to adverse events in patients treated with ceftaroline.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Ceftaroline; Cephalosporins; Hematologic Diseases; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2014 |
[Ceftaroline: new possibilities of short-term courses of antibacterial therapy in hospitalized patients with extramural pneumonia].
Topics: Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Hospitalization; Humans; Pneumonia, Bacterial; Severity of Illness Index | 2014 |
[Antibiotics for treatment of infections by methicillin-resistant Staphylococcus aureus (MRSA)].
Topics: Acetamides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Evidence-Based Medicine; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Oxazolidinones; Pneumonia, Staphylococcal; Treatment Outcome; Vancomycin | 2014 |
Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Humans; Risk Assessment; Treatment Outcome | 2014 |
Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Approval; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Product Surveillance, Postmarketing; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; United States | 2015 |
Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature.
Topics: Aged, 80 and over; Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Humans; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2015 |
Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Linezolid; Risk Factors; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2015 |
A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Drug Administration Schedule; Humans; Pneumonia; Precision Medicine; Skin Diseases, Infectious | 2015 |
Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.
Topics: Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Linezolid; Randomized Controlled Trials as Topic; Skin; Skin Diseases, Bacterial | 2015 |
Ceftaroline fosamil: A super-cephalosporin?
Topics: Adult; Ceftaroline; Cephalosporins; Humans | 2015 |
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic | 2016 |
Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Daptomycin; Female; Fluoroquinolones; Glycopeptides; Hospitalization; Humans; Iatrogenic Disease; Internal Medicine; Linezolid; Lipoglycopeptides; Male; Minocycline; Oxazolidinones; Skin Diseases, Infectious; Soft Tissue Infections; Teicoplanin; Tigecycline; Vancomycin | 2016 |
Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Vancomycin | 2016 |
New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Drug Administration Schedule; Drug Approval; Drug Combinations; Drug Resistance, Microbial; Glycopeptides; Humans; Lipoglycopeptides; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Soft Tissue Infections; Teicoplanin; United States; United States Food and Drug Administration | 2016 |
Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Female; Humans; Methicillin-Resistant Staphylococcus aureus; Salvage Therapy; Staphylococcal Infections | 2016 |
Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Topics: Animals; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Humans; Pneumonia; Soft Tissue Infections; Staphylococcal Skin Infections | 2016 |
Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Humans; Pneumonia; Randomized Controlled Trials as Topic; Staphylococcal Skin Infections | 2017 |
Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
Topics: Anti-Bacterial Agents; Bayes Theorem; Ceftaroline; Cephalosporins; Daptomycin; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Oxazolidinones; Skin Diseases, Bacterial; Staphylococcal Infections; Tetrazoles; Vancomycin | 2017 |
Ceftaroline for the treatment of methicillin-resistant
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Retrospective Studies; Staphylococcal Infections; Treatment Outcome | 2017 |
[New antibiotics - standstill or progress].
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Ceftaroline; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Resistance, Multiple, Bacterial; Ephedrine; Humans; Macrolides; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Penicillanic Acid; Phenobarbital; Staphylococcal Infections; Tazobactam; Theophylline; Triazoles | 2017 |
Current Clinical Trials on the Use of Ceftaroline in the Pediatric Population.
Topics: Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Community-Acquired Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Sepsis; Streptococcus pneumoniae | 2017 |
Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Retrospective Studies; Treatment Outcome | 2018 |
Safety and effectiveness of ceftaroline fosamil in children: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Child; Drug Resistance, Bacterial; Humans; Treatment Outcome | 2019 |
Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Pneumonia, Staphylococcal; Randomized Controlled Trials as Topic; Staphylococcus aureus; Treatment Outcome; Young Adult | 2019 |
Off-label use of ceftaroline fosamil: A systematic review.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Community-Acquired Infections; Cross Infection; Endocarditis, Bacterial; Healthcare-Associated Pneumonia; Humans; Meningitis; Off-Label Use | 2019 |
Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Drug-Related Side Effects and Adverse Reactions; Humans; Pneumonia, Staphylococcal; Staphylococcus aureus; Treatment Outcome | 2019 |
State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Ciprofloxacin; Clindamycin; Cystic Fibrosis; Humans; Linezolid; Lipoglycopeptides; Methicillin; Methicillin-Resistant Staphylococcus aureus; Rifampin; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 2020 |
Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Daptomycin; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Vancomycin | 2020 |
Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftaroline; Ceftazidime; Cephalosporins; Cyclooctanes; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Public Health; Sepsis; Tazobactam | 2020 |
Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
Topics: Ceftaroline; Cephalosporins; Child; Humans; Infant, Newborn; Methicillin-Resistant Staphylococcus aureus; Pneumonia; Soft Tissue Infections | 2021 |
Ceftaroline.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Staphylococcus aureus | 2021 |
Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials.
Topics: Adult; Bacteremia; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Humans; Pneumonia; Soft Tissue Infections; Treatment Outcome | 2022 |
Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Daptomycin; Drug Resistance; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Vancomycin | 2022 |
Ceftaroline in severe community-acquired pneumonia.
Topics: Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia | 2022 |
Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Soft Tissue Infections; Staphylococcal Infections | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
39 trial(s) available for cephalosporin c and ppi-0903
| Article | Year |
|---|---|
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin Resistance; Middle Aged; Recurrence; Skin Diseases, Infectious; Streptococcus agalactiae; Treatment Outcome; Vancomycin | 2007 |
Effect of ceftaroline on normal human intestinal microflora.
Topics: Adult; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Ceftaroline; Cephalosporins; Feces; Female; Humans; Infusions, Intravenous; Intestines; Male; Microbial Sensitivity Tests; Reference Values; Young Adult | 2010 |
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2010 |
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2010 |
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2010 |
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Bacteria; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2011 |
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Bacteria; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2011 |
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Treatment Outcome | 2011 |
Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial | 2011 |
Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Europe; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Treatment Outcome; United States | 2011 |
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Retrospective Studies; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2012 |
Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Cephalosporins; Chromatography, Liquid; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Middle Aged; Placebos; Tandem Mass Spectrometry | 2013 |
Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Female; Humans; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Odds Ratio; Pneumonia, Pneumococcal; Retrospective Studies; Treatment Outcome | 2013 |
Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval.
Topics: Adolescent; Adult; Aza Compounds; Ceftaroline; Cephalosporins; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Young Adult | 2013 |
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Male; Middle Aged; Models, Biological; Pneumonia, Bacterial; Skin Diseases, Bacterial; Young Adult | 2013 |
Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia; Young Adult | 2013 |
Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Cross-Over Studies; Double-Blind Method; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Young Adult | 2014 |
A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
Topics: Adolescent; Adult; Aged; Aging; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Half-Life; Humans; Infusions, Intravenous; Kidney; Kidney Failure, Chronic; Male; Prodrugs; Renal Dialysis; Renal Elimination; Renal Insufficiency; Severity of Illness Index; Young Adult | 2014 |
Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2014 |
Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume.
Topics: Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cross-Over Studies; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male | 2014 |
Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Skin; Staphylococcal Skin Infections; Treatment Outcome | 2015 |
Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2015 |
Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Asian People; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia; Treatment Outcome | 2015 |
A pharmacokinetic/pharmacodynamic analysis of ceftaroline prophylaxis in patients with external ventricular drains.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ceftaroline; Cephalosporins; Drainage; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Neurosurgical Procedures; Prosthesis-Related Infections; Staphylococcus; Streptococcus pneumoniae | 2015 |
Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Biotransformation; Body Mass Index; Body Weight; Ceftaroline; Cephalosporins; Computer Simulation; Creatinine; Female; Healthy Volunteers; Humans; Male; Middle Aged; Monte Carlo Method; Obesity; Obesity, Morbid; Prodrugs; Prospective Studies; Young Adult | 2015 |
Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteria; beta-Lactamase Inhibitors; beta-Lactams; Ceftaroline; Cephalosporins; Feces; Female; Gastrointestinal Microbiome; Healthy Volunteers; Humans; Male; Microbial Sensitivity Tests; Young Adult | 2015 |
Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Asian People; Biotransformation; Black or African American; Ceftaroline; Cephalosporins; China; Double-Blind Method; Drug Administration Schedule; Female; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Models, Biological; Risk Assessment; Western World; White People; Young Adult | 2015 |
An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Area Under Curve; Ceftaroline; Cephalosporins; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Half-Life; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Young Adult | 2015 |
Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.
Topics: Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cystic Fibrosis; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Young Adult | 2016 |
A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Female; Humans; Infant; Infusions, Intravenous; Male; Pneumonia, Bacterial; Treatment Outcome; Vancomycin | 2016 |
A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
Topics: Adolescent; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Female; Hospitalization; Humans; Infant; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Prospective Studies; Staphylococcus aureus; Treatment Outcome | 2016 |
A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Staphylococcus aureus; Streptococcus pyogenes; Treatment Outcome | 2016 |
Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.
Topics: Adult; Bronchoalveolar Lavage Fluid; Ceftaroline; Cephalosporins; Epithelial Cells; Female; Healthy Volunteers; Humans; Injections, Intravenous; Male | 2016 |
A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Prospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Systemic Inflammatory Response Syndrome; Treatment Outcome; Vancomycin; Young Adult | 2016 |
Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Administration Schedule; Female; Humans; Male; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2019 |
Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Double-Blind Method; Female; Humans; Infant; Infant, Newborn; Internationality; Male; Neonatal Sepsis | 2020 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
384 other study(ies) available for cephalosporin c and ppi-0903
| Article | Year |
|---|---|
In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.
Topics: Animals; Butyrates; Ceftaroline; Cephalosporins; Disease Models, Animal; Enterococcus; Male; Methicillin Resistance; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Microbial Sensitivity Tests; Oxazoles; Pneumonia, Bacterial; Staphylococcal Infections; Staphylococcus | 2004 |
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Internationality; Microbial Sensitivity Tests | 2005 |
Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Culture Media; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Serum | 2005 |
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacteria; Bacterial Proteins; Bacteroides; beta-Lactamases; Ceftaroline; Cephalosporins; Clavulanic Acid; Conjugation, Genetic; Drug Combinations; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Enterococcus; Escherichia coli; Gram-Negative Bacteria; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Mutation; Phenotype; Respiratory Tract Diseases; Staphylococcus | 2007 |
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Area Under Curve; Ceftaroline; Cephalosporins; Chromatography, High Pressure Liquid; Colony Count, Microbial; Endocarditis, Bacterial; Immunoenzyme Techniques; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Oxazolidinones; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin; Vancomycin Resistance | 2007 |
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; United States | 2008 |
Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Humans; Methicillin Resistance; Molecular Structure; Patents as Topic; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship | 2008 |
Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics.
Topics: Acetylglucosamine; Anti-Bacterial Agents; Binding Sites; Biomimetic Materials; Carbapenems; Ceftaroline; Cell Wall; Cephalosporins; Circular Dichroism; Kinetics; Methicillin Resistance; Muramic Acids; Penicillin-Binding Proteins; Peptide Synthases; Peptidoglycan; Protein Conformation; Staphylococcus aureus | 2008 |
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; United States | 2008 |
In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
Topics: Amoxicillin; Anti-Bacterial Agents; Cefotaxime; Ceftaroline; Cephalosporin Resistance; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae | 2008 |
Stability and stabilization studies of TAK-599 (Ceftaroline Fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Drug Stability; Freeze Drying; Methicillin Resistance; Prodrugs; Solubility; Spectrophotometry, Ultraviolet; Staphylococcus aureus; Water; X-Ray Diffraction | 2008 |
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Typing Techniques; Ceftaroline; Cephalosporins; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillin-Binding Proteins; Pneumococcal Infections; Streptococcus pneumoniae | 2009 |
In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
Topics: Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Culture Media; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quality Control | 2009 |
Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial | 2009 |
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftaroline; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Canada; Ceftaroline; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Ketolides; Male; Microbial Sensitivity Tests; Middle Aged; Streptococcal Infections; Streptococcus pneumoniae; Young Adult | 2009 |
In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Biological; Staphylococcus aureus; Vancomycin | 2009 |
In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and van
Topics: Acetamides; Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Endocarditis, Bacterial; Enterococcus faecalis; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Rabbits; Vancomycin; Vancomycin Resistance | 2009 |
Postantibiotic effect of ceftaroline against gram-positive organisms.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Enterococcus; Gram-Positive Cocci; Microbial Sensitivity Tests; Staphylococcus; Streptococcus pneumoniae | 2009 |
Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Ceftaroline; Cephalosporins; Female; Haplorhini; Injections, Intramuscular; Injections, Intravenous; Male; Rabbits; Rats; Rats, Sprague-Dawley | 2010 |
AmpC induction by ceftaroline.
Topics: Bacterial Proteins; beta-Lactamases; Ceftaroline; Cephalosporins; Enterobacteriaceae; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Humans; Microbial Sensitivity Tests | 2010 |
Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Inhibitory Concentration 50; Penicillin-Binding Proteins; Protein Binding; Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Ceftaroline; Ceftriaxone; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Microbial Sensitivity Tests | 2010 |
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactams; Binding, Competitive; Cefotaxime; Ceftaroline; Cephalosporins; Drug Resistance, Microbial; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillin G; Streptococcus pneumoniae | 2010 |
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Communicable Diseases, Emerging; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2010 |
In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Topics: Acetamides; Ceftaroline; Cephalosporins; Cross Infection; Daptomycin; Drug Synergism; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Staphylococcal Infections; Tobramycin; Vancomycin | 2010 |
Ceftaroline for complicated skin and skin-structure infections.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Staphylococcal Infections | 2010 |
In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
Topics: Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2010 |
Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftaroline; Cephalosporins; Drug Synergism; Enterobacteriaceae; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests | 2010 |
Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Bone and Bones; Bone Marrow; Ceftaroline; Cephalosporins; Disease Models, Animal; Female; Linezolid; Methicillin-Resistant Staphylococcus aureus; Osteomyelitis; Oxazolidinones; Rabbits; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2010 |
Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Ceftaroline; Cephalosporins; Disease Models, Animal; Endocarditis, Bacterial; Endocardium; Female; Injections, Intramuscular; Methicillin-Resistant Staphylococcus aureus; Rabbits; Staphylococcal Infections; Treatment Outcome | 2010 |
In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria, Anaerobic; Ceftaroline; Ceftriaxone; Cephalosporins; Clindamycin; Fluoroquinolones; Imipenem; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Quinolines; Tigecycline | 2011 |
Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Europe; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Population Surveillance; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; United States | 2010 |
The problem of complicated skin and skin structure infections: the need for new agents.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Skin Infections | 2010 |
Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Half-Life; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections | 2010 |
Ceftaroline fosamil: drug profile and clinical data.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rabbits; Skin Diseases, Bacterial | 2011 |
Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Infusions, Intravenous; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Skin Diseases, Bacterial; Staphylococcal Infections | 2011 |
Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Enterococcus faecalis; Gram-Negative Bacteria; Gram-Positive Bacteria; Haemophilus influenzae; Klebsiella pneumoniae; Microbial Sensitivity Tests; Moraxella catarrhalis; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes | 2011 |
Ceftaroline: potential role and implications in an era of escalating antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests | 2011 |
Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Daptomycin; Disease Models, Animal; Drug Resistance, Bacterial; Endocarditis, Bacterial; Female; Methicillin-Resistant Staphylococcus aureus; Microbial Viability; Minocycline; Rabbits; Rodent Diseases; Staphylococcal Infections; Tigecycline; Treatment Outcome | 2011 |
In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
Topics: Anti-Bacterial Agents; Canada; Ceftaroline; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Staphylococcus aureus; Time Factors | 2011 |
Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Cross Infection; Humans; In Vitro Techniques; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Staphylococcal Infections; Vancomycin Resistance | 2011 |
Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Community-Acquired Infections; Europe; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; United States | 2011 |
In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
Topics: Animals; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftaroline; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Thigh | 2011 |
Changing needs of community-acquired bacterial pneumonia: experience with ceftaroline fosamil. Preface.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Humans; Male; Microbial Sensitivity Tests; Penicillin Resistance; Pneumonia, Pneumococcal; Rabbits; Streptococcus pneumoniae | 2011 |
Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests | 2011 |
MRSA guidelines: a matter of time.
Topics: Ceftaroline; Cephalosporins; Community-Acquired Infections; Guidelines as Topic; Humans; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pneumonia; Staphylococcal Infections | 2011 |
Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Genotype; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Phenotype; Staphylococcal Infections; Staphylococcus aureus; Thigh | 2011 |
Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.
Topics: Acetamides; Bacterial Toxins; Ceftaroline; Cephalosporins; Clindamycin; Daptomycin; Electrophoresis, Gel, Pulsed-Field; Erythromycin; Exotoxins; Leukocidins; Levofloxacin; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mupirocin; Ofloxacin; Oxacillin; Oxazolidinones; Polymerase Chain Reaction; Staphylococcus aureus; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination; United States; Vancomycin | 2011 |
Ceftaroline (Teflaro): a new cephalosporin.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Pneumonia, Bacterial; Skin Diseases, Bacterial; Staphylococcal Infections | 2011 |
Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.
Topics: Anti-Bacterial Agents; Area Under Curve; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Ceftaroline; Cephalosporins; Chromatography, Liquid; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Biological; Tandem Mass Spectrometry | 2012 |
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Computer Simulation; Drug Incompatibility; Glucose Solution, Hypertonic; Humans; Infusions, Intravenous; Injections, Intravenous; Isotonic Solutions; Ringer's Solution; Saline Solution, Hypertonic | 2011 |
New drugs 2012 part I.
Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzazepines; Benzimidazoles; Benzofurans; Ceftaroline; Cephalosporins; Cyclopropanes; Drug Approval; Drug Combinations; Humans; Imidazoles; Indoles; Isoindoles; Linagliptin; Lurasidone Hydrochloride; Macrolides; Oxadiazoles; Piperazines; Proline; Purines; Quinazolines; Thiazoles; United States; Vilazodone Hydrochloride | 2012 |
Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Endocarditis, Bacterial; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Salvage Therapy; Staphylococcal Infections; Texas; Treatment Outcome | 2012 |
Early endpoints for acute bacterial skin and skin structure infections.
Topics: Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Female; Humans; Male; Skin Diseases, Bacterial; Vancomycin | 2012 |
Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Drug Administration Schedule; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Immunocompetence; Injections, Intravenous; Klebsiella; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Phenotype; Thigh | 2012 |
Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.
Topics: Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporin Resistance; Cephalosporins; Community-Acquired Infections; Culture Media; Half-Life; Humans; Microbial Sensitivity Tests; Models, Biological; Pneumonia, Pneumococcal; Streptococcus pneumoniae | 2012 |
Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Europe; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Pneumococcal; Serotyping; South Africa; Streptococcus pneumoniae; Young Adult | 2012 |
Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Ceftaroline; Cephalosporins; DNA Fingerprinting; Exotoxins; Genotype; Greece; Humans; Leukocidins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Sequence Data; Molecular Typing; Penicillin-Binding Proteins; Protein Binding; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcal Infections; Virulence Factors | 2012 |
Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Enterobacteriaceae; Genomic Instability; Microbial Sensitivity Tests; Mutant Proteins; Phenotype; Porins; Selection, Genetic | 2012 |
Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2012 |
Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.
Topics: Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Haemophilus influenzae; Methicillin Resistance; Microbial Sensitivity Tests; Moraxella catarrhalis; Staphylococcus aureus; United States | 2012 |
In vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010-2011.
Topics: Ceftaroline; Ceftriaxone; Cephalosporins; Microbial Sensitivity Tests; Penicillins; Streptococcus pneumoniae | 2012 |
Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studies.
Topics: Age Factors; Aztreonam; Bacterial Toxins; Ceftaroline; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Exotoxins; Female; Genotype; Humans; Leukocidins; Male; Methicillin-Resistant Staphylococcus aureus; Polymerase Chain Reaction; Staphylococcal Skin Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin | 2012 |
Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
Topics: Aminoglycosides; Analysis of Variance; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Daptomycin; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Vancomycin | 2012 |
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
Topics: Acinetobacter; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftaroline; Cephalosporins; Chromosomes, Bacterial; Drug Combinations; Gram-Negative Bacterial Infections; Humans; Isoenzymes; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Plasmids; Pseudomonas aeruginosa; Staphylococcal Infections | 2012 |
In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Europe; Genotype; Humans; Microbial Sensitivity Tests; Middle East; Multilocus Sequence Typing; Skin Diseases, Bacterial | 2012 |
The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Arthritis, Infectious; Bacteremia; Ceftaroline; Cephalosporins; Endocarditis, Bacterial; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Osteomyelitis; Pneumonia, Staphylococcal; Prodrugs; Retrospective Studies; Staphylococcal Infections; Treatment Outcome | 2013 |
Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2012 |
Ceftaroline applications for therapy in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Drug Approval; Humans; United States | 2012 |
Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Staphylococcus aureus; Young Adult | 2012 |
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Streptococcus pneumoniae; United States | 2012 |
Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; United States | 2012 |
Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Dose-Response Relationship, Drug; Female; Humans; Immunocompromised Host; Lung; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neutropenia; Pneumonia, Staphylococcal; Protein Binding | 2012 |
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Longitudinal Studies; Microbial Sensitivity Tests; Pneumococcal Infections; Streptococcus pneumoniae; United States | 2013 |
Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; United States | 2013 |
Ceftaroline versus isolates from animal bite wounds: comparative in vitro activities against 243 isolates, including 156 Pasteurella species isolates.
Topics: Animals; Anti-Bacterial Agents; Bites and Stings; Ceftaroline; Cephalosporins; Colony Count, Microbial; Humans; Indicator Dilution Techniques; Microbial Sensitivity Tests; Pasteurella; Quality Control; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus | 2012 |
[Antibiotics: the race continues].
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Streptococcal Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2012 |
An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit?
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Approval; Humans; Minocycline; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Tigecycline; United States | 2012 |
Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
Topics: Aminoacyltransferases; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacterial Proteins; Cathelicidins; Ceftaroline; Cell Membrane; Cell Wall; Cephalosporins; Colony Count, Microbial; Daptomycin; Drug Combinations; Drug Synergism; Fluorescent Dyes; Genome, Bacterial; High-Throughput Nucleotide Sequencing; Methicillin-Resistant Staphylococcus aureus; Microbial Viability; Models, Biological; Mutation; Vancomycin; Vancomycin Resistance | 2013 |
Early response of ceftaroline fosamic in the treatment of soft-tissue infections.
Topics: Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Community-Acquired Infections; Endpoint Determination; Humans; Pneumonia; Randomized Controlled Trials as Topic; Retrospective Studies; Soft Tissue Infections; Time Factors; Treatment Outcome; Vancomycin | 2012 |
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ceftaroline; Cephalosporins; Community-Acquired Infections; Europe; Humans; Microbial Sensitivity Tests; Respiratory Tract Infections | 2013 |
Inhibition of Streptococcus pneumoniae penicillin-binding protein 2x and Actinomadura R39 DD-peptidase activities by ceftaroline.
Topics: Actinomycetales; Acylation; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Kinetics; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Serine-Type D-Ala-D-Ala Carboxypeptidase; Species Specificity; Streptococcus pneumoniae | 2013 |
High ceftaroline non-susceptibility in Staphylococcus aureus isolated from acute skin infections in 15 tertiary hospitals in China.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; China; Drug Resistance, Bacterial; Female; Humans; Inpatients; Male; Microbial Sensitivity Tests; Outpatients; Staphylococcal Skin Infections; Staphylococcus aureus; Tertiary Care Centers | 2013 |
Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Topics: Acetamides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Monocytes; Oxazolidinones; Vancomycin | 2013 |
Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Debridement; Drug Resistance, Bacterial; Endocarditis, Bacterial; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Osteomyelitis; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin | 2013 |
Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.
Topics: Anti-Infective Agents; Azabicyclo Compounds; Ceftaroline; Cephalosporins; Drug Combinations; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Streptococcus pneumoniae | 2013 |
Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.
Topics: Anti-Bacterial Agents; Boron Compounds; Ceftaroline; Cell Wall; Cephalosporins; Drug Combinations; Drug Synergism; Fluorescent Dyes; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxacillin; Vancomycin; Vancomycin Resistance | 2013 |
Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Biological; Staphylococcal Infections; Staphylococcus aureus | 2013 |
Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Escherichia coli; Europe; Gram-Positive Cocci; Humans; Klebsiella; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Skin Infections | 2013 |
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Topics: Anti-Bacterial Agents; Asia; Ceftaroline; Cephalosporins; Community-Acquired Infections; Haemophilus influenzae; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moraxella catarrhalis; Respiratory Tract Infections; Skin Diseases, Bacterial; Soft Tissue Infections; South Africa; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2013 |
Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Load; Bacterial Toxins; Ceftaroline; Ceftriaxone; Cephalosporins; Clostridioides difficile; Clostridium Infections; Gastrointestinal Tract; Healthy Volunteers; Human Activities; Humans; Microbial Sensitivity Tests; Models, Theoretical | 2013 |
Ceftaroline - a cause for neutropenia.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Neutropenia; Pneumonia, Bacterial | 2013 |
Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bacteroides fragilis; beta-Lactam Resistance; Ceftaroline; Cephalosporins; Diabetes Complications; Drug Synergism; Enterobacter; Foot Diseases; Humans; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Morganella; Prevotella | 2013 |
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Topics: Acetamides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Hospitals; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2013 |
Ceftaroline-induced eosinophilic pneumonia.
Topics: Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Ceftaroline; Cephalosporins; Glucocorticoids; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Pulmonary Eosinophilia; Staphylococcal Infections | 2013 |
Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline.
Topics: Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cathelicidins; Ceftaroline; Cell Membrane; Cephalosporins; Daptomycin; Drug Resistance, Bacterial; Drug Synergism; Endocarditis, Bacterial; Enterococcus faecalis; Gentamicins; Humans; Male; Microbial Sensitivity Tests; Middle Aged | 2013 |
Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Costs and Cost Analysis; Drug Therapy, Combination; Economics, Hospital; Formularies, Hospital as Topic; Humans; Length of Stay; Models, Economic; Skin Diseases, Bacterial; Vancomycin | 2013 |
Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant streptococcus pneumoniae in an experimental rabbit meningitis model.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Meningitis; Penicillin Resistance; Penicillins; Rabbits; Streptococcus pneumoniae | 2013 |
Evaluation of the effect of serum proteins on the antibacterial activity and pharmacodynamics of ceftaroline against Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Blood Proteins; Ceftaroline; Ceftriaxone; Cephalosporins; Microbial Sensitivity Tests; Protein Binding; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2013 |
In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Canada; Ceftaroline; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Public Health Surveillance; Retrospective Studies | 2013 |
Efficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Ceftaroline; Cephalosporins; Disease Models, Animal; Escherichia coli; Klebsiella Infections; Klebsiella pneumoniae; Meninges; Meningitis, Escherichia coli; Permeability; Rabbits; Treatment Outcome | 2013 |
In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteroides fragilis; Ceftaroline; Cephalosporins; Coinfection; Drug Administration Schedule; Drug Combinations; Enterobacter cloacae; Escherichia coli; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Immunocompromised Host; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Treatment Outcome | 2013 |
Activity of ceftaroline against Enterococcus faecium PBP5.
Topics: Ampicillin Resistance; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; Ceftaroline; Cephalosporins; Enterococcus faecium | 2013 |
Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Dose-Response Relationship, Drug; Europe; Gram-Negative Bacteria; Gram-Positive Bacteria; Israel; Microbial Sensitivity Tests; Structure-Activity Relationship; Turkey | 2014 |
Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Retrospective Studies; Skin; Skin Diseases, Bacterial; Skin Diseases, Infectious; Staphylococcal Infections; Young Adult | 2013 |
How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function.
Topics: Acylation; Allosteric Regulation; Catalytic Domain; Ceftaroline; Cephalosporins; Crystallography, X-Ray; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Muramic Acids; Penicillin-Binding Proteins; Peptidoglycan; Substrate Specificity | 2013 |
Ceftaroline plus avibactam demonstrates bactericidal activity against pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic/pharmacodynamic model.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacteria, Anaerobic; Bacteroides fragilis; Ceftaroline; Cephalosporins; Microbial Sensitivity Tests; Prevotella | 2014 |
In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Daptomycin; Drug Combinations; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Statistical; Vancomycin; Vancomycin Resistance | 2014 |
[In vitro activity of ceftaroline to MRSA isolates: a multicenter study].
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Turkey | 2013 |
Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Epidemiological Monitoring; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mupirocin; Staphylococcal Infections; United States; Vancomycin; Vancomycin Resistance | 2014 |
Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Humans; Mice; Microbial Sensitivity Tests; Models, Statistical; Monte Carlo Method; Renal Insufficiency, Chronic; Severity of Illness Index; Staphylococcus aureus; Streptococcus pneumoniae | 2014 |
Activity of ceftaroline against community associated and healthcare associated methicillin resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2014 |
Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011).
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Epidemiological Monitoring; Global Health; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2014 |
Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cefotaxime; Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests; Serotyping; Streptococcus pneumoniae | 2014 |
Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.
Topics: Anti-Bacterial Agents; Ceftaroline; Cell Wall; Cephalosporins; Daptomycin; Drug Synergism; Enterococcus faecium; In Vitro Techniques; Membrane Fluidity; Microbial Sensitivity Tests; Vancomycin Resistance | 2014 |
Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Therapy, Combination; Emergency Medical Services; Epidural Abscess; Female; Humans; Laminectomy; Long-Term Care; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Neck Pain; Salvage Therapy; Staphylococcal Infections; Thrombocytopenia; Tomography, X-Ray Computed | 2014 |
In vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Toxins; Ceftaroline; Cephalosporins; Exotoxins; Leukocidins; Male; Methicillin-Resistant Staphylococcus aureus; Pneumonia; Rabbits; Staphylococcal Infections | 2014 |
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Soft Tissue Infections; United States | 2014 |
Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cefoxitin; Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests; Oxacillin; Penicillins; Staphylococcal Infections; Staphylococcus; United States; United States Food and Drug Administration | 2014 |
In vitro activity of ceftaroline against Burkholderia pseudomallei.
Topics: Anti-Bacterial Agents; Burkholderia pseudomallei; Ceftaroline; Cephalosporins; Humans; In Vitro Techniques; Inhibitory Concentration 50; Microbial Sensitivity Tests | 2014 |
Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.
Topics: Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Drug Resistance, Multiple, Bacterial; Erythromycin; Levofloxacin; Microbial Sensitivity Tests; Penicillins; Streptococcus pneumoniae; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Which antibiotic for hospital acquired pneumonia caused by MRSA?
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cross Infection; Daptomycin; Humans; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Minocycline; Oxazolidinones; Pneumonia, Staphylococcal; Tigecycline; Vancomycin; Virginiamycin | 2014 |
Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteria; Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests; Skin Diseases, Bacterial; United States | 2014 |
Eosinophilic pneumonia induced by ceftaroline.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Ceftaroline; Cephalosporins; Drug Hypersensitivity; Female; Humans; Hypoxia; Methicillin-Resistant Staphylococcus aureus; Methylprednisolone; Penicillins; Pulmonary Disease, Chronic Obstructive; Pulmonary Eosinophilia; Staphylococcal Infections | 2014 |
Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Skin Diseases, Bacterial | 2014 |
Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
Topics: Academic Medical Centers; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ceftaroline; Cephalosporins; Child; Child, Preschool; Female; Hospitals; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Middle Aged; Respiratory Tract Infections; United States; Young Adult | 2014 |
Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying β-lactamases prevalent in the United States.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftaroline; Cephalosporins; Drug Combinations; Enterobacteriaceae Infections; Escherichia coli; Humans; Klebsiella; Microbial Sensitivity Tests; Prevalence; Proteus mirabilis; United States | 2014 |
Ceftaroline fosamil: just another intravenous antibiotic.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Injections, Intravenous | 2013 |
A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Biofilms; Ceftaroline; Cephalosporins; Methicillin-Resistant Staphylococcus aureus | 2014 |
Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cross Infection; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Pneumonia, Staphylococcal; Retrospective Studies | 2015 |
Ceftaroline-heteroresistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2014 |
Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cohort Studies; Community-Acquired Infections; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Staphylococcus aureus; Streptococcus pneumoniae; Young Adult | 2014 |
Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Computer Simulation; Daptomycin; Drug Combinations; Endocarditis, Bacterial; Half-Life; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Vancomycin | 2014 |
Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Endocarditis, Bacterial; Female; Humans; Male; Methicillin Resistance; Middle Aged; Salvage Therapy; Staphylococcal Infections; Staphylococcus; Treatment Outcome | 2014 |
[Ceftaroline, a new broad-spectrum cephalosporin in the era of multiresistance].
Topics: Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections | 2014 |
[Antimicrobial spectrum of ceftaroline. In vitro activity against methicillin-resistant staphylococci].
Topics: Ceftaroline; Cephalosporins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests | 2014 |
[Ceftaroline breakpoints].
Topics: Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests | 2014 |
[Role of ceftaroline in skin and soft tissue infections].
Topics: Ceftaroline; Cephalosporins; Humans; Skin Diseases, Bacterial; Soft Tissue Infections | 2014 |
[Potential utility of ceftaroline fosamil in osteoarticular infections].
Topics: Arthritis; Bone Diseases, Infectious; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections | 2014 |
[Ceftaroline fosamil in community-acquired and nosocomial pneumonia].
Topics: Animals; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Pneumonia, Staphylococcal; Streptococcus pneumoniae | 2014 |
Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests; Quality Control; Staphylococcus aureus | 2014 |
Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; Ceftaroline; Cephalosporins; DNA, Bacterial; Drug Resistance, Bacterial; Genome, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Molecular; Penicillin-Binding Proteins; Sequence Analysis, DNA; Staphylococcal Infections | 2014 |
Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Ceftaroline; Ceftriaxone; Cephalosporins; Humans; Microbial Sensitivity Tests; Molecular Epidemiology; Pneumococcal Infections; Serogroup; Serotyping; Streptococcus pneumoniae; United States | 2014 |
Antimicrobial activity of ceftaroline and other anti-infective agents against microbial pathogens recovered from the surgical intensive care patient population: a prevalence analysis.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ceftaroline; Cephalosporins; Critical Care; Humans; Microbial Sensitivity Tests; Prevalence | 2014 |
A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection.
Topics: Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Staphylococcal; Treatment Outcome | 2014 |
Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Methicillin-Resistant Staphylococcus aureus; Models, Molecular; Molecular Conformation; Mutation; Penicillin-Binding Proteins; Protein Conformation; X-Ray Diffraction | 2014 |
Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacteremia; Cathelicidins; Ceftaroline; Cephalosporins; Daptomycin; Drug Therapy, Combination; Female; Humans; Male; Mice; Middle Aged; Salvage Therapy; Staphylococcal Infections; Staphylococcus | 2014 |
Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Ceftaroline; Cephalosporins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation | 2014 |
Ceftaroline for the treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus.
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Endocarditis, Bacterial; Frail Elderly; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Prosthesis-Related Infections; Staphylococcal Infections; Treatment Outcome | 2014 |
[In vitro activity of ceftaroline against Spanish isolates of Staphylococcus aureus: a multicenter study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ceftaroline; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Staphylococcus aureus; Young Adult | 2015 |
Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2015 |
Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Female; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Penicillin-Binding Proteins; Staphylococcal Infections; Staphylococcus aureus | 2014 |
Ceftaroline-Fosamil efficacy against methicillin-resistant Staphylococcus aureus in a rabbit prosthetic joint infection model.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Disease Models, Animal; Drug Resistance, Bacterial; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Prosthesis-Related Infections; Rabbits; Staphylococcal Infections; Vancomycin | 2014 |
Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Longitudinal Studies; Microbial Sensitivity Tests; Pneumococcal Infections; Pneumococcal Vaccines; Serogroup; Serotyping; Streptococcus pneumoniae; United States; Vaccines, Conjugate | 2014 |
A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline.
Topics: Aged; Agranulocytosis; Anti-Bacterial Agents; Arthritis, Infectious; Ceftaroline; Cephalosporins; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Neutropenia; Off-Label Use | 2014 |
PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.
Topics: Adult; Amino Acid Substitution; Anti-Bacterial Agents; Base Sequence; Binding Sites; Ceftaroline; Cephalosporins; Cystic Fibrosis; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; MutS DNA Mismatch-Binding Protein; Penicillin-Binding Proteins; Sequence Analysis, DNA; Staphylococcal Infections; Young Adult | 2014 |
Allergic interstitial nephritis due to ceftaroline.
Topics: Ceftaroline; Cephalosporins; Drug Hypersensitivity; Humans; Male; Middle Aged; Nephritis, Interstitial | 2014 |
Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Topics: Adolescent; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Child; Child, Preschool; Drug Resistance, Bacterial; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Serotyping; Skin Diseases, Bacterial; Soft Tissue Infections | 2014 |
The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Bacterial; Drug Synergism; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation | 2015 |
Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Drug Utilization; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Skin Diseases, Bacterial | 2014 |
Successful use of ceftaroline for the treatment of MRSA meningitis secondary to an infectious complication of lumbar spine surgery.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Meningitis, Bacterial; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Staphylococcal Infections; Surgical Wound Infection; Treatment Outcome | 2015 |
Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftaroline; Cephalosporins; Disease Models, Animal; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Reproducibility of Results; Thigh | 2014 |
Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Case-Control Studies; Ceftaroline; Cephalosporins; Demography; Disease Eradication; Female; Glycopeptides; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Staphylococcal Infections; Time Factors; Treatment Failure; Vancomycin | 2014 |
In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Area Under Curve; Biomimetic Materials; Ceftaroline; Ceftriaxone; Cephalosporins; Colony Count, Microbial; Extracellular Fluid; Humans; Methicillin-Resistant Staphylococcus aureus; Models, Statistical; Respiratory Mucosa; Vancomycin | 2014 |
Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Length of Stay; Male; Middle Aged; Obesity; Patient Discharge; Retrospective Studies; Sex Factors; Skin Diseases, Bacterial; Socioeconomic Factors; United States; Young Adult | 2014 |
Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Drug Tolerance; Female; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Salvage Therapy; Staphylococcal Infections; Vancomycin | 2015 |
Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Body Mass Index; Ceftaroline; Cephalosporins; Cohort Studies; Comorbidity; Diabetic Foot; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Obesity; Overweight; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus | 2015 |
Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cerebrospinal Fluid; Humans; Meningitis, Bacterial; Plasma; Ventriculoperitoneal Shunt | 2015 |
[AstraZeneca--Research focus infectious diseases].
Topics: Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Drug Approval; Drug Industry; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Translational Research, Biomedical | 2014 |
[Antimicrobial properties of ceftaroline fosamil].
Topics: Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cross Infection; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2014 |
[Efficacy of ceftaroline in treating complicated skin and soft tissue infections].
Topics: Aztreonam; Ceftaroline; Cephalosporins; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin | 2014 |
[Zinforo™ (ceftaroline fosamil)--A new beta-lactam-cephalosporin with MRSA activity].
Topics: Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Staphylococcal Infections | 2014 |
[Therapy of skin and soft tissue infections from surgeon's point of view].
Topics: Algorithms; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Opportunistic Infections; Postoperative Care; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections | 2014 |
[Two clinical example cases].
Topics: Aged; Arthroplasty, Replacement, Hip; Ceftaroline; Cephalosporins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femoral Neck Fractures; Humans; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Opportunistic Infections; Reoperation; Soft Tissue Infections; Staphylococcal Infections; Surgical Wound Infection | 2014 |
Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia; Renal Insufficiency; Retrospective Studies; Skin Diseases, Bacterial; Young Adult | 2015 |
[Evaluation E-test method to determine the antimicrobial activity of ceftaroline against methicillin-resistant strains of Staphylococcus aureus].
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2014 |
Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ceftaroline; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation, Missense; Penicillin-Binding Proteins; Staphylococcal Infections; Switzerland | 2015 |
Desensitization to ceftaroline in a patient with multiple medication hypersensitivity reactions.
Topics: Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections | 2015 |
Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37.
Topics: Adult; Aged; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cathelicidins; Ceftaroline; Cephalosporins; Cytochromes c; Drug Interactions; Female; Humans; Male; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Middle Aged; Streptococcus pneumoniae; Survival Analysis | 2015 |
Accuracy of the Thermo Fisher Scientific (Sensititre™) dry-form broth microdilution MIC product when testing ceftaroline.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Reproducibility of Results; United States | 2015 |
Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ceftaroline; Ceftriaxone; Cephalosporins; Enterobacteriaceae; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus pneumoniae; United States | 2015 |
A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; China; Cities; Cross Infection; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Typing; Staphylococcal Skin Infections; Virulence Factors | 2015 |
Bactericidal activity of ceftaroline against mature Staphylococcus aureus biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Ceftaroline; Cephalosporins; Colony Count, Microbial; Humans; Microbial Viability; Staphylococcus aureus | 2015 |
Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Europe; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Monte Carlo Method; Pneumonia, Bacterial; Skin Diseases, Bacterial; Treatment Outcome | 2015 |
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Microbial Sensitivity Tests; Respiratory Tract Infections; Skin Diseases, Bacterial; United States | 2015 |
Impact of β-lactamase inhibition on the activity of ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftaroline; Cephalosporins; Mycobacterium; Mycobacterium tuberculosis | 2015 |
Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Ceftaroline; Ceftazidime; Cephalosporins; Escherichia coli; Humans; Microbial Sensitivity Tests | 2015 |
Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests | 2015 |
β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactams; Ceftaroline; Cephalosporins; Daptomycin; Enterococcus faecalis; Enterococcus faecium; Ertapenem; Microbial Sensitivity Tests; Vancomycin; Vancomycin-Resistant Enterococci | 2015 |
Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests; Sepsis; Staphylococcal Infections; Staphylococcus aureus; United States | 2015 |
Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Registries; Retrospective Studies; Skin Diseases, Bacterial | 2016 |
Mycotic pseudoaneurysm by vancomycin-intermediate Staphylococcus aureus: a rare cause of persistent bacteraemia.
Topics: Aneurysm, False; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Debridement; Diagnosis, Differential; Drug Resistance, Microbial; Femoral Artery; Humans; Ligation; Male; Middle Aged; Mycoses; Staphylococcus aureus; Thigh; Vancomycin; Venous Thrombosis | 2015 |
Comparative Efficacy of Ceftaroline with Linezolid against Staphylococcus aureus and Methicillin Resistant Staphylococcus aureus.
Topics: Acetamides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Staphylococcal Infections; Staphylococcus aureus | 2015 |
The combination of ampicillin plus ceftaroline is synergistic against Enterococcus faecalis.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Colony Count, Microbial; Drug Synergism; Enterococcus faecalis; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Microbial Viability | 2015 |
Pre-Use Susceptibility to Ceftaroline in Clinical Staphylococcus aureus Isolates from Germany: Is There a Non-Susceptible Pool to be Selected?
Topics: Ceftaroline; Cephalosporins; Genes, Bacterial; Germany; Humans; Microbial Sensitivity Tests; Phylogeny; Prevalence; Staphylococcal Infections; Staphylococcus aureus | 2015 |
Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cohort Studies; Drug Resistance, Multiple, Bacterial; Female; Health Records, Personal; Humans; Inpatients; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Off-Label Use; Pneumonia, Ventilator-Associated; Retrospective Studies; Risk Factors; United States | 2015 |
Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia.
Topics: Anti-Bacterial Agents; Australia; Ceftaroline; Cephalosporin Resistance; Cephalosporins; Cross Infection; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Prospective Studies; Staphylococcal Infections | 2015 |
Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
Topics: Anti-Bacterial Agents; Biofilms; Ceftaroline; Cephalosporins; Daptomycin; Drug Therapy, Combination; Half-Life; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Rifampin; Vancomycin | 2015 |
[New antibiotic in treatment of surgical infection: the first experience].
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin Resistance; Middle Aged; Prodrugs; Prosthesis-Related Infections; Staphylococcal Infections; Surgical Procedures, Operative; Surgical Wound Infection; Treatment Outcome | 2015 |
Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin.
Topics: Adult; Agranulocytosis; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clindamycin; Drug Therapy, Combination; Female; Fournier Gangrene; Humans; Male; Meningitis, Bacterial; Middle Aged; Retrospective Studies; Staphylococcal Infections; Surgical Wound Infection; Young Adult | 2015 |
Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ceftaroline; Cephalosporins; Genetic Variation; Genotype; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Staphylococcal Infections | 2015 |
Successful treatment of meticillin-resistant Staphylococcus aureus (MRSA) aortic prosthetic valve endocarditis with prolonged high-dose daptomycin plus ceftaroline therapy.
Topics: Aged; Anti-Bacterial Agents; Aortic Valve; Bicuspid Aortic Valve Disease; Ceftaroline; Cephalosporins; Daptomycin; Endocarditis; Heart Defects, Congenital; Heart Valve Diseases; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbial Viability; Staphylococcal Infections; Treatment Outcome | 2015 |
Ceftaroline Activity against mecC-Containing Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; DNA, Bacterial; Genes, Bacterial; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus | 2015 |
Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Skin Diseases, Bacterial; United Kingdom; Young Adult | 2015 |
Could ceftaroline be an alternative therapy for linezolid resistant Staphylococcus epidermidis infections in Intensive Care Medicine?
Topics: Anti-Bacterial Agents; Bacteremia; Body Fluids; Catheter-Related Infections; Ceftaroline; Cephalosporins; Critical Care; Cross Infection; Daptomycin; Drug Resistance, Multiple, Bacterial; Exudates and Transudates; Humans; Linezolid; Methicillin; Minocycline; Staphylococcal Infections; Staphylococcus epidermidis; Tigecycline; Vancomycin | 2015 |
Ceftaroline in vitro activity against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococci: a short report from Italy.
Topics: Ceftaroline; Cephalosporins; Coagulase; Humans; Italy; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus | 2017 |
Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Sensitivity and Specificity; United Kingdom | 2015 |
Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.
Topics: Anti-Bacterial Agents; Australia; Ceftaroline; Cephalosporins; Clone Cells; Drug Resistance, Multiple, Bacterial; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Phenotype; Staphylococcal Infections | 2015 |
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Hospitalization; Humans; Latin America; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Public Health Surveillance; Staphylococcal Infections | 2015 |
Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA.
Topics: Africa; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; Carrier State; Ceftaroline; Cephalosporins; Genotype; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Multilocus Sequence Typing; Mutation, Missense; Penicillin-Binding Proteins; Sequence Analysis, DNA; Staphylococcal Infections | 2016 |
PBP2a substitutions linked to ceftaroline resistance in MRSA isolates from the UK.
Topics: Amino Acid Substitution; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Staphylococcal Infections; United Kingdom | 2016 |
Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline.
Topics: Alleles; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; Ceftaroline; Cephalosporins; Microbial Sensitivity Tests; Mutation Rate; Penicillin-Binding Proteins; Selection, Genetic; Serial Passage; Staphylococcus aureus | 2016 |
Neutropenia Associated with Long-Term Ceftaroline Use.
Topics: Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Leukocyte Count; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Neutropenia; Neutrophils; Retrospective Studies; Staphylococcal Infections; Time Factors | 2016 |
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Asia, Southeastern; Bacterial Proteins; beta-Lactam Resistance; Ceftaroline; Cephalosporins; Epidemiological Monitoring; Gene Expression; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Penicillin-Binding Proteins; Staphylococcal Infections | 2016 |
In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Epidemiological Monitoring; Europe; Humans; Microbial Sensitivity Tests; Prevalence; Skin Diseases, Bacterial; Soft Tissue Infections; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
Simultaneous determination of ceftaroline, daptomycin, linezolid and rifampicin concentrations in human plasma by on-line solid phase extraction coupled to high-performance liquid chromatography-tandem mass spectrometry.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Chromatography, High Pressure Liquid; Daptomycin; Humans; Linezolid; Rifampin; Solid Phase Extraction; Tandem Mass Spectrometry | 2016 |
Ceftaroline activity on certain respiratory tract and wound infection agents at the minimum inhibitory concentration level.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Respiratory Tract Infections; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Streptococcus; Wound Infection | 2015 |
Tricuspid and mitral endocarditis due to methicillin-resistant Staphylococcus aureus exhibiting vancomycin-creep phenomenon.
Topics: Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Endocarditis, Bacterial; Fatal Outcome; Heart Valve Diseases; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Mitral Valve; Staphylococcal Infections; Tricuspid Valve; Vancomycin | 2015 |
In vitro activity of ceftaroline against staphylococci from prosthetic joint infection.
Topics: Anti-Bacterial Agents; Arthritis; Ceftaroline; Cephalosporins; Disk Diffusion Antimicrobial Tests; Humans; Prosthesis-Related Infections; Staphylococcal Infections; Staphylococcus aureus; Staphylococcus epidermidis | 2016 |
Intravenous ceftaroline 200 mg administered every 8 h is safe and adequate for meticillin-resistant Staphylococcus aureus bloodstream infections in end-stage renal failure patients on haemodialysis: a case study.
Topics: Administration, Intravenous; Aged; Bacteremia; Ceftaroline; Cephalosporins; Discitis; Drug Administration Schedule; Endocarditis; Humans; Kidney Failure, Chronic; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Renal Dialysis; Staphylococcal Infections | 2015 |
Ceftaroline activity tested against viridans group streptococci from US hospitals.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cross Infection; Humans; Microbial Sensitivity Tests; Streptococcal Infections; United States; Viridans Streptococci | 2016 |
Elevated International Normalized Ratio values in a patient receiving warfarin and ceftaroline.
Topics: Aged; Anticoagulants; Ceftaroline; Cephalosporins; Drug Interactions; Drug Therapy, Combination; Dyspnea; Humans; International Normalized Ratio; Male; Warfarin | 2016 |
Effects of Subinhibitory Concentrations of Ceftaroline on Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Ceftaroline; Cephalosporins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests | 2016 |
[Septic shock in 23 year old female patient after surgical correction of the nasal septum effectively treated in the intensive care unit].
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Intensive Care Units; Meningitis, Bacterial; Nasal Septum; Nasal Surgical Procedures; Postoperative Complications; Shock, Septic; Young Adult | 2015 |
Regulatory Mutations Impacting Antibiotic Susceptibility in an Established Staphylococcus aureus Biofilm.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Catheter-Related Infections; Catheters; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Bacterial; Humans; Mice; Microbial Sensitivity Tests; Sigma Factor; Staphylococcal Infections; Staphylococcus aureus | 2016 |
Comparative in-vitro activity of ceftaroline against Staphylococcus aureus isolates from India.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; India; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2016 |
The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.
Topics: Africa; Anti-Bacterial Agents; beta-Lactam Resistance; Ceftaroline; Cephalosporins; Endopeptidases; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Recombinant Proteins; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus Phages | 2016 |
Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefazolin; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Ertapenem; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nafcillin; Staphylococcal Infections; Vancomycin; Vancomycin-Resistant Enterococci | 2016 |
Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Microbial Viability; Models, Biological; Models, Theoretical | 2016 |
Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Minocycline; Skin; Staphylococcal Skin Infections; Streptococcal Infections; Streptococcus; Tigecycline; United States | 2016 |
In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporin Resistance; Cephalosporins; Genes, Bacterial; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Mutation; Sequence Analysis, DNA; Spondylitis; Staphylococcal Infections | 2016 |
Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance.
Topics: Bacterial Proteins; beta-Lactams; Ceftaroline; Cephalosporins; Genome, Bacterial; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Models, Molecular; Mutation; Open Reading Frames; Penicillin-Binding Proteins; Promoter Regions, Genetic; Sequence Analysis, DNA | 2016 |
Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model.
Topics: Ampicillin; Anti-Bacterial Agents; Cefepime; Ceftaroline; Ceftriaxone; Cephalosporins; Enterococcus faecalis; Gentamicins; Microbial Sensitivity Tests | 2016 |
Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Retrospective Studies; Soft Tissue Infections; Standard of Care; Treatment Outcome | 2016 |
Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cross Infection; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Staphylococcal Infections; Staphylococcus; United States | 2016 |
Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus | 2016 |
Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Dosage Calculations; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Microdialysis; Middle Aged; Muscle, Skeletal; Subcutaneous Tissue | 2016 |
High incidence of neutropenia in patients with prolonged ceftaroline exposure.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Boston; Ceftaroline; Cephalosporins; Female; Humans; Incidence; Male; Middle Aged; Neutropenia; Retrospective Studies; Risk Factors; Young Adult | 2016 |
The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Ceftaroline; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sulbactam | 2016 |
Multi-center and multi-method evaluation of in vitro activities of ceftaroline against S. aureus.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests; Reproducibility of Results; Staphylococcus aureus | 2016 |
Susceptibility patterns of Staphylococcus aureus biofilms in diabetic foot infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Biofilms; Ceftaroline; Cephalosporins; Diabetic Foot; Gentamicins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus aureus | 2016 |
Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014).
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Community-Acquired Infections; Cross Infection; Epidemiological Monitoring; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pneumonia, Staphylococcal; Staphylococcal Infections; Staphylococcal Skin Infections; United States | 2016 |
Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Ceftaroline; Ceftazidime; Cephalosporins; Escherichia coli; Gene Expression; Humans; Microbial Sensitivity Tests | 2016 |
Effects of ceftaroline on the innate immune and on the inflammatory responses of bronchial epithelial cells exposed to cigarette smoke.
Topics: Active Transport, Cell Nucleus; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; beta-Defensins; Bronchioles; Bronchiolitis; Ceftaroline; Cell Line; Cell Line, Transformed; Cells, Cultured; Cephalosporins; Gene Expression Regulation; Humans; Immunity, Innate; Interleukin-8; Lipopolysaccharides; NF-kappa B; Prodrugs; Promoter Regions, Genetic; Respiratory Mucosa; Tobacco Smoke Pollution; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2016 |
In vitro activity of ceftaroline against mecC-positive MRSA isolates.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests | 2016 |
Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Ceftaroline; Cephalosporins; Genotype; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Epidemiology; Mupirocin; Staphylococcal Infections; Sweden; Vancomycin | 2016 |
In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.
Topics: Africa; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Epidemiological Monitoring; Humans; Microbial Sensitivity Tests; Middle East; Respiratory Tract Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; DNA Mutational Analysis; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Selection, Genetic; Serial Passage; Staphylococcus aureus | 2016 |
Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Clinical Trials as Topic; Community-Acquired Infections; Computer Simulation; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Models, Biological; Pneumonia, Bacterial; Skin Diseases, Bacterial; Staphylococcus aureus; Streptococcus pneumoniae | 2017 |
Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays.
Topics: Ampicillin; Anti-Bacterial Agents; Biological Assay; Ceftaroline; Cephalosporins; Drug Combinations; Drug Synergism; Enterococcus faecalis; Enterococcus faecium; Gram-Positive Bacterial Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Vancomycin Resistance | 2017 |
Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Osteoarthritis; Outpatients; Patient Readmission; Retrospective Studies; Treatment Outcome; Vancomycin | 2016 |
In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Therapy, Combination; Humans; Linezolid; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Vancomycin | 2016 |
In vitro activity of ceftaroline against clinical Staphylococcus aureus isolates collected during a national survey conducted in Belgian hospitals.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Belgium; Ceftaroline; Cephalosporins; DNA, Bacterial; Drug Resistance, Bacterial; Female; Genotype; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Typing; Prevalence; Sequence Analysis, DNA; Staphylococcal Infections; Staphylococcus aureus | 2017 |
Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Genotype; Hospitals, University; Humans; Italy; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Typing; Mutation; Penicillin-Binding Proteins; Prevalence; Staphylococcal Infections | 2017 |
Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Incompatibility; Infusions, Intravenous; Organophosphates; Oxazoles; Pharmaceutical Solutions | 2016 |
Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Europe; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Staphylococcal; Staphylococcal Skin Infections; Staphylococcus aureus; Young Adult | 2017 |
Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Topics: Aged; Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Endocarditis; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Staphylococcal Infections; Vancomycin | 2017 |
Combination Therapy With Vancomycin and Ceftaroline for Refractory Methicillin-resistant Staphylococcus aureus Bacteremia: A Case Series.
Topics: Abscess; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Salvage Therapy; Staphylococcal Infections; Vancomycin | 2017 |
The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftaroline; Ceftazidime; Cephalosporins; Computer Simulation; Drug Therapy, Combination; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2017 |
Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N
Topics: Amino Acid Motifs; Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftaroline; Ceftazidime; Cephalosporins; Clavulanic Acid; Cloning, Molecular; Drug Combinations; Escherichia coli; Gene Expression; Kinetics; Mutation; Recombinant Proteins; Reverse Genetics; Substrate Specificity | 2017 |
Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by biofilm-producing methicillin-resistant Staphylococcus epidermidis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Biofilms; Ceftaroline; Cephalosporins; Disease Models, Animal; Female; Foreign Bodies; Methicillin Resistance; Mice, Inbred C57BL; Microbial Sensitivity Tests; Random Allocation; Sepsis; Soft Tissue Infections; Staphylococcal Infections; Staphylococcus epidermidis; Treatment Outcome; Vancomycin | 2016 |
Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Female; Hospitalization; Humans; Length of Stay; Male; Methicillin-Resistant Staphylococcus aureus; Michigan; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Salvage Therapy; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2017 |
Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
Topics: Adult; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Ceftaroline; Cephalosporins; Cross Infection; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Endocarditis, Bacterial; Gene Expression; Humans; Male; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Staphylococcal Infections; Vancomycin | 2017 |
Ceftriaxone Etest non-susceptible methicillin susceptible Staphylococcus aureus time-kill responses.
Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Ceftaroline; Ceftriaxone; Cefuroxime; Cephalosporins; Cephalothin; Disk Diffusion Antimicrobial Tests; Humans; Oxacillin; Staphylococcus aureus | 2017 |
Disseminated MRSA infection with purulent pericarditis.
Topics: Adult; Ceftaroline; Cephalosporins; Female; Humans; Methicillin-Resistant Staphylococcus aureus; Pericarditis; Prednisolone; Staphylococcal Infections; Treatment Outcome | 2017 |
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
Topics: Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Haemophilus influenzae; Hospitals; Humans; Infant; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Respiratory Tract Infections; Retrospective Studies; Skin Diseases, Bacterial; Staphylococcal Infections; Streptococcus pneumoniae; United States | 2017 |
Oral-Only Linezolid-Rifampin Is Highly Effective Compared with Other Antibiotics for Periprosthetic Joint Infection: Study of a Mouse Model.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Disease Models, Animal; Doxycycline; Drug Combinations; Linezolid; Methicillin-Resistant Staphylococcus aureus; Mice; Prosthesis-Related Infections; Rifampin; Staphylococcal Infections; Treatment Outcome | 2017 |
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Chlamydial Pneumonia; Chlamydophila pneumoniae; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Legionella pneumophila; Macrolides; Male; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2017 |
Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clindamycin; Erythromycin; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Skin Infections; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2017 |
Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System.
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Epidemiologic Studies; Female; Humans; Male; Middle Aged; United States; Veterans Health | 2017 |
Salvage therapy for complex bone and joint infections with ceftaroline: a multicentre, observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Diseases, Infectious; Ceftaroline; Cephalosporins; Female; Humans; Joint Diseases; Male; Middle Aged; Prosthesis-Related Infections; Retrospective Studies; Salvage Therapy; Staphylococcal Infections; Treatment Outcome | 2017 |
Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Microbial; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Osteomyelitis; Prognosis; Retrospective Studies; Staphylococcal Infections; United States | 2018 |
Rapid developing empyema by group F beta Streptococcus anginosus group.
Topics: Administration, Intravenous; Adult; Ceftaroline; Cephalosporins; Chest Tubes; Dental Caries; Empyema, Pleural; Humans; Male; Streptococcal Infections; Streptococcus anginosus | 2017 |
Ceftaroline modulates the innate immune and host defense responses of immunocompetent cells exposed to cigarette smoke.
Topics: Anti-Bacterial Agents; beta-Defensins; Ceftaroline; Cell Line, Tumor; Cell Survival; Cephalosporins; Dose-Response Relationship, Drug; Host-Pathogen Interactions; Humans; Immunity, Innate; Immunocompetence; Immunologic Factors; Lipopolysaccharides; Macrophages; Monocytes; Smoke; Smoking; Toll-Like Receptor 2; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2017 |
Identification and determination of related substances of ceftaroline fosamil in medicinal product by high performance liquid chromatography with diode array detection and tandem mass spectrometry.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Chromatography, High Pressure Liquid; Community-Acquired Infections; Tandem Mass Spectrometry | 2017 |
The use of cardiac MRI in a rare case of primary mural endocarditis.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Echocardiography, Transesophageal; Endocarditis, Bacterial; Heart Ventricles; Humans; Immunocompetence; Magnetic Resonance Imaging; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Staphylococcal Infections; Stroke Volume; Treatment Refusal | 2017 |
The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Models, Biological; Mycobacterium avium; THP-1 Cells | 2017 |
Intraosteoblastic activity of daptomycin in combination with oxacillin and ceftaroline against MSSA and MRSA.
Topics: Anti-Bacterial Agents; Ceftaroline; Cell Line; Cephalosporins; Colony Count, Microbial; Daptomycin; Drug Synergism; Humans; Methicillin Resistance; Microbial Viability; Osteoblasts; Oxacillin; Staphylococcus aureus | 2017 |
Rate and Incidence of Adverse Reactions Associated With Ceftaroline Exposure: Importance of Cutaneous Manifestations.
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Exanthema; Female; Humans; Hypersensitivity; Incidence; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Neutropenia; Staphylococcal Infections | 2018 |
Successful treatment of community-acquired methicillin-resistant Staphylococcus aureus purulent myopericarditis.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Myocarditis; Pericardial Effusion; Pericardiectomy; Pericarditis; Postoperative Complications; Staphylococcal Infections; Steroids; Treatment Outcome; Vancomycin | 2017 |
Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Staphylococcal; Rifampin | 2018 |
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Humans; Membranes, Artificial; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Biological; Staphylococcal Infections; Staphylococcus aureus | 2017 |
Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Chromatography, Liquid; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Monitoring; Female; Half-Life; Humans; Male; Mass Spectrometry; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Prospective Studies; Treatment Outcome | 2018 |
Topics: Academic Medical Centers; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Tigecycline; United States | 2018 |
Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to ceftaroline collected in Russia during 2010-2014.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporin Resistance; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Russia; Staphylococcal Infections | 2018 |
Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefazolin; Ceftaroline; Cephalosporins; Daptomycin; Female; Humans; Incidence; Leukocyte Count; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Neutropenia; Retrospective Studies; Staphylococcal Infections; Vancomycin | 2018 |
DISC: Describing Infections of the Spine treated with Ceftaroline.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Male; Middle Aged; Osteomyelitis; Retrospective Studies; Spinal Diseases; Staphylococcal Infections | 2018 |
Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus: A Pharmacokinetic Case Series.
Topics: Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Critical Illness; Female; Humans; Infant; Intensive Care Units, Pediatric; Male; Methicillin-Resistant Staphylococcus aureus; Prospective Studies; Retrospective Studies; Staphylococcal Infections; Treatment Outcome | 2018 |
In vitro synergism and anti-biofilm activity of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Biofilms; Ceftaroline; Ceftriaxone; Cephalosporins; Cohort Studies; Drug Synergism; Endocarditis, Bacterial; Enterococcus faecalis; Female; Gentamicins; Gram-Positive Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged | 2018 |
Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Salvage Therapy; Staphylococcal Infections | 2018 |
β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
Topics: beta-Lactams; Cefazolin; Cefepime; Ceftaroline; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nafcillin; Staphylococcal Infections; Vancomycin | 2018 |
Prevention of High-Level Daptomycin-Resistance Emergence In Vitro in Streptococcus mitis-oralis by Using Combination Antimicrobial Strategies.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Combinations; Drug Resistance, Bacterial; Gentamicins; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Organophosphates; Oxazoles; Rifampin; Streptococcus mitis; Streptococcus oralis; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Oxygenator Impact on Ceftaroline in Extracorporeal Membrane Oxygenation Circuits.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Equipment Design; Extracorporeal Membrane Oxygenation; Humans; Oxygenators, Membrane | 2018 |
GW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against β-Lactam-Resistant Staphylococcus aureus.
Topics: Adjuvants, Pharmaceutic; Autoradiography; beta-Lactam Resistance; Ceftaroline; Cephalosporins; Drug Synergism; fms-Like Tyrosine Kinase 3; Methicillin-Resistant Staphylococcus aureus; Oxacillin; Protein Kinase Inhibitors; Pyridazines; Small Molecule Libraries; Staphylococcal Infections | 2018 |
Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Reference Standards; Staphylococcal Infections | 2018 |
Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates from Spain and molecular characterisation of borderline susceptible and resistant strains.
Topics: Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Spain; Staphylococcal Infections; Tertiary Care Centers | 2018 |
Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Clinical Trials as Topic; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Soft Tissue Infections; Staphylococcal Infections; Staphylococcal Skin Infections; Staphylococcus aureus; Young Adult | 2019 |
In Vitro Activities of Ceftaroline/Avibactam, Ceftazidime/Avibactam, and Other Comparators Against Pathogens From Various Complicated Infections in China.
Topics: Acinetobacter; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; China; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitalization; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Public Health Surveillance | 2018 |
Antibiotics Stimulate Formation of Vesicles in
Topics: Anti-Bacterial Agents; Bacteriophages; Ceftaroline; Cephalosporins; Cytoplasmic Vesicles; Daptomycin; DNA, Bacterial; Floxacillin; Humans; Lysogeny; Peptidoglycan; Staphylococcus aureus | 2019 |
Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cerebral Ventricles; Cerebral Ventriculitis; Cerebrospinal Fluid; Chromatography, Liquid; Drainage; Female; Humans; Infusions, Intravenous; Intensive Care Units; Male; Meningitis, Bacterial; Middle Aged; Models, Theoretical; Neurosurgical Procedures; Postoperative Complications; Tandem Mass Spectrometry; Young Adult | 2019 |
Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Endocarditis, Bacterial; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; United States; Young Adult | 2019 |
Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Skin Diseases, Bacterial; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2019 |
Genomic characterization of inpatient evolution of MRSA resistant to daptomycin, vancomycin and ceftaroline.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Evolution, Molecular; Female; Genomics; Humans; Inpatients; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Staphylococcal Infections; Vancomycin | 2019 |
Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Multicenter Studies as Topic; Osteomyelitis; Registries; Retrospective Studies; Risk Factors; Staphylococcal Infections; Staphylococcus aureus; Young Adult | 2019 |
Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Daptomycin; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Neoplasms; Staphylococcal Infections; Vancomycin | 2019 |
Ceftaroline as salvage therapy for complicated MRSA bacteremia: case series and analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; New Jersey; Salvage Therapy; Staphylococcal Infections; Treatment Failure | 2019 |
Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Global Health; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Soft Tissue Infections; Staphylococcal Skin Infections; Young Adult | 2019 |
In vitro activity of ceftaroline in combination with other antimicrobials active against Staphylococcus spp.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Synergism; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcus; Staphylococcus aureus; Vancomycin | 2020 |
Genotypic analysis of Italian MRSA strains exhibiting low-level ceftaroline and ceftobiprole resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Genotype; Humans; Italy; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Staphylococcal Infections | 2019 |
Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Daptomycin; Drug Synergism; Endocarditis; Fosfomycin; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2019 |
Introduction.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Pneumonia, Bacterial; Pseudomonas; Staphylococcal Infections; Staphylococcus aureus | 2019 |
Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Male; Middle Aged; Retrospective Studies; Skin; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2019 |
Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015-2016.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia; Public Health Surveillance | 2019 |
Ceftaroline-associated Encephalopathy in Patients With Severe Renal Impairment.
Topics: Anti-Bacterial Agents; Brain Diseases; Ceftaroline; Cephalosporins; Humans; Renal Insufficiency | 2020 |
Effect of Ceftaroline, Vancomycin, Gentamicin, Macrolides, and Ciprofloxacin against Methicillin-Resistant
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Gentamicins; Humans; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Vancomycin | 2020 |
Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Typing Techniques; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Gene Expression; Genes, Bacterial; Humans; Linezolid; Methicillin; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Phylogeny; Rifampin; Staphylococcal Infections; Tetracycline; Turkey; Vancomycin; Vancomycin Resistance; Virginiamycin | 2020 |
Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?
Topics: Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Standard of Care; Staphylococcal Infections; Staphylococcus aureus | 2019 |
Reply to Kalil et al., "Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?"
Topics: Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Standard of Care; Staphylococcal Infections; Staphylococcus aureus | 2019 |
Is Daptomycin plus Ceftaroline the Way To Go for Methicillin-Resistant Staphylococcus aureus Bacteremia?
Topics: Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Standard of Care | 2019 |
Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centres (2015-2018).
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; United States | 2020 |
Multidrug-Resistant Staphylococcus epidermidis Ventriculostomy-Related Infection Successfully Treated by Intravenous Ceftaroline after Failure of Daptomycin Treatment.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Female; Humans; Retreatment; Staphylococcal Infections; Staphylococcus epidermidis; Surgical Wound Infection; Ventriculostomy | 2020 |
Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
Topics: Anti-Bacterial Agents; Bacteremia; Brazil; Ceftaroline; Cephalosporins; Daptomycin; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Monte Carlo Method; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2020 |
Ceftaroline for treating older patients with community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia | 2020 |
Characterizing the role of porin mutations in susceptibility of beta lactamase producing Klebsiella pneumoniae isolates to ceftaroline and ceftaroline-avibactam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Mutation; Porins | 2020 |
Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain.
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Italy; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Oseltamivir; Pneumococcal Infections; Pneumonia; Retrospective Studies; Spain; Staphylococcal Infections; Streptococcus pneumoniae | 2020 |
Ceftaroline versus vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in an experimental MRSA meningitis model.
Topics: Animals; Ceftaroline; Cephalosporins; Meningitis; Methicillin-Resistant Staphylococcus aureus; Rabbits; Staphylococcal Infections; Vancomycin | 2020 |
Study of susceptibility to antibiotics and molecular characterization of high virulence Staphylococcus aureus strains isolated from a rural hospital in Ethiopia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Ethiopia; Exotoxins; Hospitals, Rural; Humans; Leukocidins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Multilocus Sequence Typing; Penicillins; Phylogeny; Staphylococcal Infections; Staphylococcus aureus; Virulence | 2020 |
In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model.
Topics: Ampicillin; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Enterococcus faecalis; Gentamicins; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2020 |
Combination of ceftaroline and daptomycin as treatment for complicated osteomyelitis.
Topics: Ceftaroline; Cephalosporins; Daptomycin; Drug Combinations; Female; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Osteomyelitis | 2021 |
Susceptibility of clinical isolates of meticillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum β-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from Antimicrobial Testing Leadership and Surveillance (AT
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Humans; Klebsiella pneumoniae; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Respiratory Tract Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Taiwan | 2020 |
In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Haemophilus; Humans; Klebsiella pneumoniae; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Respiratory Tract Infections; Soft Tissue Infections; Staphylococcus aureus; Taiwan | 2021 |
Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; beta-Lactams; Ceftaroline; Cephalosporins; Daptomycin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecium; Ertapenem; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Rats; Sequence Alignment; Transcriptome | 2020 |
A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Cohort Studies; Daptomycin; Drug Therapy, Combination; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Staphylococcal Infections; Treatment Outcome | 2020 |
Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteria.
Topics: Adolescent; Anti-Infective Agents; Azabicyclo Compounds; Bacteria; Bacterial Proteins; beta-Lactamases; Candida; Ceftaroline; Ceftazidime; Cephalosporins; Child; Child, Preschool; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Oxacillin; Sepsis; United States | 2020 |
A snapshot survey of antimicrobial susceptibility among respiratory
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcus aureus | 2020 |
Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Ireland; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcus; Staphylococcus aureus; Streptococcus pneumoniae; United Kingdom | 2020 |
Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project.
Topics: Antimicrobial Stewardship; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Clinical Protocols; Drug Combinations; Humans; Interrupted Time Series Analysis; Medication Systems; Oxazolidinones; Practice Patterns, Physicians'; Spain; Tazobactam; Teicoplanin; Tetrazoles | 2020 |
Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis.
Topics: Administration, Intravenous; Adolescent; Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Infant; Infant, Newborn; Male; Methicillin-Resistant Staphylococcus aureus; Retrospective Studies; Staphylococcal Infections; Vancomycin; Young Adult | 2020 |
Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Hospitals; Humans; Kuwait; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2020 |
Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2020 |
In vitro activity of ceftaroline and ceftobiprole against clinical isolates of Gram-positive bacteria from infective endocarditis: are these drugs potential options for the initial management of this disease?
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Endocarditis, Bacterial; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests | 2020 |
Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Ceftaroline; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Genome, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation; Staphylococcal Infections | 2020 |
Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016).
Topics: Adult; Aged; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteria; Ceftaroline; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Time Factors; Young Adult | 2020 |
Differential effects of antibiotics on neutrophils exposed to lipoteichoic acid derived from Staphylococcus aureus.
Topics: Anti-Bacterial Agents; CD11b Antigen; Ceftaroline; Cephalosporins; Daptomycin; Humans; L-Selectin; Lipopolysaccharides; Neutrophils; Phagocytosis; Staphylococcal Infections; Staphylococcus aureus; Teichoic Acids; Vancomycin | 2020 |
High-level ceftaroline resistance in a paediatric patient with invasive methicillin-resistant Staphylococcus aureus infection without previous ceftaroline exposure.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Infant; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Vancomycin | 2021 |
Prevalence and molecular epidemiology of ceftaroline non-susceptible methicillin-resistant Staphylococcus aureus isolates, first clinical report from Iran.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; DNA, Bacterial; Humans; Iran; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Prevalence; Staphylococcal Infections | 2020 |
A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment.
Topics: Ceftaroline; Cephalosporins; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Hepacivirus; Hepatitis C; Humans; Molecular Dynamics Simulation; Oligopeptides; SARS-CoV-2 | 2021 |
In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015-2018.
Topics: Africa; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests; Middle East; Respiratory Tract Infections | 2021 |
Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy.
Topics: Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Continuous Renal Replacement Therapy; Critical Illness; Dose-Response Relationship, Drug; Humans; Intensive Care Units | 2021 |
Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
Topics: Adolescent; Adult; Age Factors; Anti-Bacterial Agents; Area Under Curve; Ceftaroline; Cephalosporins; Child; Child, Preschool; Computer Simulation; Female; Humans; Infant; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Models, Biological; Renal Insufficiency | 2021 |
Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital.
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Prescriptions; Retrospective Studies; Staphylococcus aureus; Tertiary Care Centers | 2021 |
Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Daptomycin; Drug Synergism; Drug Therapy, Combination; Female; Gentamicins; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Rifampin; Salvage Therapy; Standard of Care; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2021 |
Characterization of an osteomyelitis case caused by dalbavancin, ceftaroline, and vancomycin non-susceptible methicillin-resistant Staphylococcus aureus.
Topics: Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Osteomyelitis; Teicoplanin; Vancomycin; Whole Genome Sequencing | 2021 |
In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Streptococcus | 2021 |
In vitro activity of ceftaroline against methicillin-resistant and methicillin-susceptible Staphylococcus aureus clinical isolates from a tertiary hospital in Greece.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Greece; Humans; Methicillin; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Tertiary Care Centers | 2021 |
Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an
Topics: Anti-Bacterial Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Ceftaroline; Cephalosporins; Humans; Lung; Methicillin-Resistant Staphylococcus aureus; Microdialysis; Pharmaceutical Preparations | 2021 |
Comparison of Etest and broth microdilution for evaluating the susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to ceftaroline and of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa to ceftazidime/avibactam.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftaroline; Ceftazidime; Cephalosporins; Disk Diffusion Antimicrobial Tests; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Streptococcus pneumoniae | 2021 |
Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
Topics: Adolescent; Anti-Bacterial Agents; Area Under Curve; Ceftaroline; Cephalosporins; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Glomerular Filtration Barrier; Half-Life; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Patient Acuity; Renal Insufficiency | 2021 |
Nonirritant concentrations and performance of ceftaroline skin tests in patients with an immediate β-lactam hypersensitivity.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftaroline; Cephalosporins; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Skin Tests | 2021 |
Ceftaroline Pharmacokinetics in a Critically Ill Adult Receiving Continuous Venovenous Hemodiafiltration.
Topics: Acute Kidney Injury; Adult; Ceftaroline; Cephalosporins; Continuous Renal Replacement Therapy; Critical Illness; Humans | 2022 |
Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Hospital Mortality; Humans; Male; Middle Aged; Retrospective Studies; Standard of Care; Staphylococcal Infections | 2022 |
Successful treatment with daptomycin and ceftaroline of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) endocarditis: a case report.
Topics: Ceftaroline; Cephalosporins; Daptomycin; Endocarditis; Humans; Staphylococcus aureus; Vancomycin-Resistant Staphylococcus aureus | 2021 |
Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adults.
Topics: Adult; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cohort Studies; Cystic Fibrosis; Humans; Lung; Methicillin-Resistant Staphylococcus aureus; Retrospective Studies; Staphylococcal Infections; Vancomycin | 2022 |
Incidence and risk factors for mortality in patients treated with combined ceftaroline for Gram-positive infective endocarditis.
Topics: Adult; Aged; Aged, 80 and over; Ceftaroline; Cephalosporins; Endocarditis; Endocarditis, Bacterial; Female; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Risk Factors; Shock, Septic | 2022 |
Ceftaroline removal during plasmapheresis.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Plasmapheresis | 2022 |
Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Vancomycin | 2022 |
Ceftaroline versus standard therapy for pneumococcal meningitis in critically ill patients.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Critical Illness; Humans; Meningitis, Pneumococcal | 2022 |
Emergence of methicillin-resistant Staphylococcus epidermidis resistant to linezolid: activity of ceftaroline versus ceftobiprole in a French University Hospital.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Hospitals; Humans; Linezolid; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus epidermidis | 2022 |
Population pharmacokinetic/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Critical Care; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Monte Carlo Method; Pneumonia; Renal Insufficiency; Streptococcus pneumoniae | 2022 |
Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an
Topics: Adenosine Monophosphate; Ampicillin; Anti-Bacterial Agents; Ceftaroline; Ceftriaxone; Cephalosporins; Drug Synergism; Enterococcus faecalis; Ertapenem; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Clindamycin; Genomics; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2022 |
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Topics: Ampicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Klebsiella pneumoniae; Levofloxacin; Meropenem; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Tazobactam; Tigecycline | 2022 |
Ceftaroline as salvage therapy for methicillin susceptible Staphylococcus aureus complicated bacteremia.
Topics: Anti-Bacterial Agents; Bacteremia; Cefazolin; Ceftaroline; Cephalosporins; Daptomycin; Humans; Methicillin; Retrospective Studies; Salvage Therapy; Staphylococcal Infections; Staphylococcus aureus | 2022 |
Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020).
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Hospitals; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; United States | 2023 |
Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Retrospective Studies; Staphylococcal Infections; Vancomycin | 2023 |
In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Ceftaroline; Cephalosporins; Child; Child, Preschool; Endocarditis; Humans; Kingella kingae; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests | 2023 |
Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests | 2023 |
Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Ceftaroline; Cephalosporins; Child; Daptomycin; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2023 |
Use of ceftaroline in complex central nervous system infections.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2023 |
Clinical results with the use of ceftaroline and ceftobiprole: real-life experience in a tertiary care hospital.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Retrospective Studies; Tertiary Care Centers | 2023 |
Real-world experience of therapeutic drug monitoring and PK/PD achievement of ceftaroline administered by different infusion regimens in patients with confirmed infections caused by Gram-positive bacteria.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Monitoring; Female; Humans; Infusions, Parenteral; Male; Monobactams | 2023 |